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Screening Intervention Report and Website 
This Screening Intervention report outlines the piloting of screening models and test 
positive follow-up models as part of the Chlamydia Screening in Ireland Pilot Study 
conducted between 2008 and 2009. Further information including more detail on the 
methods and results can be found in the following accompanying reports on the 
Health Protection Surveillance Centre (HPSC) website.
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Chlamydia Screening in Ireland Pilot Study. Summary Integrated Report 
Chlamydia Screening in Ireland Pilot Study. Background Studies: Acceptability 
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Chlamydia Screening in Ireland Pilot Study. Economic Evaluation 
 
Other resources on the website include additional information on the implementation 
of screening, a toolkit for organising screening in non-clinical settings and links to 
published articles from the study. 
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1. Introduction 
This report summarises the findings of the Pilot Screening Intervention conducted in 
Ireland between 2008 and 2009 as part of the Chlamydia Screening in Ireland Pilot 
study. The studies aimed to pilot screening models and to evaluate their feasibility and 
effectiveness.  
The study was commissioned by the Health Protection Surveillance Centre (HPSC) 
and overseen by the Health Research Board (HRB).  It was carried out by a team from 
the Division of Population Health Sciences at the Royal College of Surgeons (RSCI) 
in Ireland, the College of Medicine, Nursing and Health Sciences at the National 
University of Ireland Galway, and Consultants in Public Health Medicine from the 
Health Service Executive (HSE).
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 Ethical approval for study components was 
provided by Research Ethics Committees of the RCSI, NUI Galway and the Irish 
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the reports and related publications and other resources can be found at: 
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Z/HepatitisHIVAIDSandSTIs/SexuallyTransmittedInfections/Chlamydia/Publications/ 
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2. Screening Study Methods  
2.1 Screening studies in clinical settings 
2.1.1 Study area and population 
For the purpose of the study, primary care settings were categorised as urban and rural 
based on their location in relation to the local city boundaries. Urban based general 
practices were located within the Galway city borough (i.e. high population density 
area) and rural based practices were categorised were located outside the city 
boundary.  
 
Figure 1. Geographical area (Galway city and county) of pilot screening  
In 2007, the total population of young people aged 18-29 in Galway city and county 
was 41,999, with similar numbers of males (21,259) and females (20,740) [1]. The 
demographic profile in figure 2 shows the population of young people aged 18-29 in 
the city and surrounding county where screening project was implemented. High 
proportions of the city population were in the screening age range. 
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Figure 2. Population of Galway County by age 
2.1.2 Recruitment of service providers  
A full-time Research Health Adviser (RHA), who was an experienced health adviser 
with a master’s qualification that included training in research methods, was 
appointed to oversee the implementation of the screening pilot intervention. 
Following pre-pilot interviews with local service providers on screening design
3
 
screening activities commenced with the recruitment of general practices. Of thirteen 
training practices approached initially, seven agreed to participate in the study. Two 
student health units (SHU), one family planning clinic (FPC) also agreed to 
participate in pilot screening.  
Several months of screening delivered a much lower rate of tests (screened patients) 
per general practice than had been anticipated.  The RHA discussed this with practice 
staff that raised issues such as lack of time and not remembering to make the 
screening offer. This led to adaptations in the process such as reminder prompts 
(computer stickers for providers to remind to offer screening) and adaptations to 
forms (to reduce the form filling). 
With offer rates still low, additional providers were recruited.  Letters of introduction 
(134) were then sent all other GPs and registered GP practice nurses in Galway city 
and county, followed by a call made by the RHA to discuss potential participation. 
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The study was also advertised in local Continuing Medical Education meetings for 
GPs, an Irish College of General Practitioners conference, and a regional practice 
nurse meeting. 
A further 22 general practices were recruited, leading to a total of twenty nine general 
practices participating in the study.  However, 6 of these practices did not screen any 
participants and withdrew from the study; leaving a total of 23 general practices in the 
study.   
2.1.3 Opportunistic testing model 
The opportunistic testing model required providers to offer chlamydia screening to 
young people aged 18-29 years attending the clinical setting. Screening was to be 
offered by either a practice nurse or general practitioner (GP) at the end of a 
consultation with an eligible patient regardless of the purpose of the visit. 
Specimens were urines or cervical swabs where a smear test was being taken. Urine 
samples were to be taken following a two hour void interval. Use of self-taken vulva-
vaginal swabs was explored but not used in the pilot due to concerns over the 
detection method: at the time it was not validated for vaginal swabs. 
A study implementation pack for the Pilot Screening Intervention was designed and 
distributed to the participating practices/settings.  This contained standard operating 
procedures (SOP) which included algorithms and guidance notes, a supply of 
microbiology request forms, patient information leaflets, and care management 
pathways (flow charts).  
The contents of the pack drew on or took into account lessons learned from an earlier 
screening project in an Irish Higher Education Institute (HEI) setting [2], the English 
National Chlamydia Screening Programme [3] and the British Association for Sexual 
Health and HIV (BASHH) screening guidelines[4]. Providers had been given the 
opportunity to review and comment on drafts of materials during the pre-screening 
interviews, and were consulted regularly throughout the design phase. 
Patient leaflets were developed entitled Free Chlamydia Testing (Appendix A) and 
Receiving Your Result (Appendix B), which outlined key messages on chlamydia 
testing. Positive images of young people were used and additional information on 
locally based sexually transmitted infection (STI) testing services and sexual health 
support networks were provided on the back of the leaflets. 
Several sets of core data were required for recording and test reporting.  A coded, 
anonymous chlamydia request form was developed (Appendix C) that recorded 
details including date of birth, sex, specimen taker, reason for test (screen or contact 
of screen positive), specimen type and mobile phone number. Each screening site was 
allocated a unique combined site/patient code that was pre-printed on the chlamydia 
request form, the self-administered anonymous questionnaire (see below) and 
microbiology forms. Participants who accepted the offer of screening were allocated 
this unique code as no commonly used unique identifier exists within the Irish health 
services.  
Demographic and risk factor data were collected from participants through a short 
self-administered anonymous questionnaire (Appendix D) in order to evaluate the 
utility of a risk factor pre-screening approach. Envelopes were provided to ensure 
confidentiality.  
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The screening model entailed service providers (GPs and practice nurses) 
opportunistically offering a test during, or at the end of a general consultation with a 
patient. Those eligible to participate were given an information leaflet to read and the 
chance to ask any questions before accepting or declining an offer. If participants 
agreed to take part in the study, a urine sample was provided by the participant or a 
cervical swab was taken if a smear test was being done. Consent was implied by 
reading the leaflet and agreeing to supply a sample.  
Providers recorded relevant details and filled out the chlamydia request form, 
retaining a copy for their records, and filing a copy for the RHA. Specimens were 
refrigerated immediately and sent to the Microbiology Department at the Galway 
University Hospital within twenty four hours. 
Patients in whom chlamydia was not detected were contacted by their chosen method 
of communication (SMS text, phone call or letter) and given their result. Participants 
with a positive result were contacted also by their chosen method by a practice nurse 
or GP from the relevant screening site, and were invited to return to be given the 
result and offered treatment and follow-up by the RHA.  
2.1.4 Introduction of screening  
Screening commenced in July 2008 in the seven initial settings, and subsequently in 
all twenty nine sites that agreed to participate.  The RHA made an introductory visit to 
each screening site, delivering supplies, introducing the screening to providers, and 
answering queries.  
Each screening site received a screening box with laboratory and treatment supplies, 
an implementation pack, advertising posters and patient information leaflets, as well 
as clinical materials. Posters and leaflets were provided to advertise the study in the 
waiting rooms of health care settings 
In the context of this pilot screening study, the providers’ participation was optional 
and largely unremunerated. Each provider received €25 for a positive case detected to 
cover the treatment consultation, which was free to patients / study cases. 
As a support to participating practices and an incentive to participate, all practices 
were offered the opportunity for a staff member to participate on the Sexually 
Transmitted Infection Foundation (STIF) course accredited by the British Association 
for Sexual Health and HIV (BASHH). Participation was not linked to performance 
targets. Five GPs, seven practice nurses, and one GP trainee completed the STIF 
course. 
The RHA visited sites and communicated regularly with staff during the screening 
period and was available to provide support and information by mobile phone. Some 
sites were visited more frequently than others, depending on screening activity. Visits 
were made to collect research data and to discuss screening with providers.  
Initial queries from providers were mainly about operational issues such as form 
filling and use of codes. As the pilot progressed visits were made only when requested 
however phone calls to sites were made regularly. Throughout the study letters were 
sent to providers concerning modifications made to protocols based on feedback 
received from sites. 
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Urine specimens were obtained from all participating men and most women, unless a 
cervical swab was appropriate.  These specimens were transported to and processed at 
a regional university hospital microbiology laboratory.   
Results were communicated to the clinician in the clinical settings where the 
screening had been taken, who took responsibility for case management as is routine 
practice.  Participants were informed of their results by the clinic staff, using the 
patient’s preferred communication method such as text message or phone call.   
2.1.5 Management (treatment) of positives cases 
The management of participants who tested positive was coordinated by each 
screening site, following the Standard Operating Procedures (SOP) manual and 
treatment protocols (Appendix E). 
Patients were given the appropriate antibiotic (usually Azithromycin), free of charge 
and on site, along with the information leaflet Receiving Your Results (Appendix B).  
This provided a detailed explanation of chlamydia infection with particular emphasis 
on the long term implications for their partners(s). All positive cases were given the 
option by the providers to speak to the RHA for further counselling and information.   
2.1.6 Further STI screening  
Further STI testing of all positive cases was recommended, in compliance with 
standard international practice. A copy of the BASHH Guidelines [4] was distributed 
to clinical staff at all screening sites for reference and information.   
Screening sites also had the options of referring patients to the regional genitourinary 
medicine (GUM) clinic or to offer further STI testing on site. Providers were 
requested to provide a referral letter if a patient was referred to the GUM clinic. The 
referral process to the GUM clinic was two fold: (i) at the treatment consultation, 
providers discussed with the positive case the need for further STI testing; and (ii) the 
RHA also followed up and provided support and advice on further STI testing with 
positive cases. In some cases, appointments for further STI testing at the GUM clinic 
were made by the research health adviser. 
2.1.7 Retesting of positive cases 
The US Centre for Disease Control and Prevention [5] recommends rescreening of 
positive cases at three months. Studies in the US have reported a high prevalence of 
chlamydia infection in women who were treated for chlamydia in the preceding 
months. The majority of infections that are detected within three months of treatment 
are due to re-infection, frequently occurring because the patient’s sex partners were 
not treated, or because the patient has sex with a new partner infected with chlamydia 
[5].  
As there are no Irish data on intervals for screening, participants were offered repeat 
testing between three months and six months after treatment. This was not a test of 
cure, but a test to detect re-infection. Participants were given the option to attend for 
retesting either at their GP or the local GUM clinic.  
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2.1.8 Partner notification 
Partner notification is a key element in the identification, management and control of 
STIs [6]s. In this process people who are known to have been exposed to a STI are 
notified and invited to attend STI testing services.  
The BASSH guideline for the management of Chlamydia trachomatis (CT) genital 
tract infection [7] was followed for the pilot study. This recommends that, where the 
index case is asymptomatic, all sexual partners over the previous six months should 
be contacted. This time period may be extended depending on a participant’s sexual 
history (last previous sexual partner).  
Two methods of partner notification were used for the pilot study, patient referral and 
provider referral, depending on the preference of the patient. Both partner notification 
systems involved discussions to identify partners at risk and partner follow up.   
Patient referral 
Patient referral is the method where positive patients are offered the choice of 
notifying their current and previous partner(s) themselves. Index cases were offered 
community contact cards (see below) by the providers to give to their previous/current 
partner(s).  
Community contact cards 
Community contact cards were designed specifically for the study (Appendix F) and 
were based on the system used by GUM clinics in Ireland and internationally. The 
purpose of the community contact card is to give the contact sufficient information to 
find a service and book an appointment to get tested and treated for chlamydia. It also 
aims to enable the issuing screening site of the contact to track attendance.  
Chlamydia was named on the contact card as a British research study had found that 
more contacts attended when the infection (chlamydia) was named on the contact slip 
[8].  Providers were instructed to write the site code/patient ID of the index case on 
the contact card to link contact cards with index cases and assist in tracking the 
process. 
Provider referral  
Provider referral is an alternative approach to partner notification, which is conducted 
in GUM clinics. It is the process where a health care professional (rather than the 
patient) informs a contact about their possible exposure to infection while not 
revealing the identity of the index patient. The partners are then advised they may 
have been exposed to chlamydia and should attend either a GP or GUM clinic for 
testing and treatment. The usual process for this is a telephone call. 
In this study the community-based RHA was available to conduct partner notification 
by phone. Providers who did not wish to carry out partner notification referred 
positive cases to the RHA, passing the mobile phone and other relevant information 
(i.e. time to call) of the index case to her.  
The RHA phoned the index case to discuss the recent diagnosis, partner notification 
options and preferences, follow-up visit (usually to the GUM clinic) for further STI 
tests, the need for a later retest, and other relevant sexual health education. A phone-
call protocol was devised which allowed the RHA to systematically follow up each 
patient (Appendix G). Forms for assessing partner risk and partner notification 
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outcomes were designed (Appendix H). Completed forms and all patient records were 
stored securely in the RHA’s office. 
The following information was recorded: 
 All actions, including successful and unsuccessful attempts to contact the person 
by telephone or other method 
 The outcome of actions, including whether contact was made, what information 
was given and the patient’s response. 
 Discussions on case management and partner notification with member(s) of the 
multi-disciplinary team. 
In addition, the RHA was available to conduct on site training for practice staff where 
requested and was available to provide support to primary care staff during the study. 
Two providers (both practice nurses) undertook onsite training for doing partner 
notification.   
Standards and protocols on the following areas were included in the Standard 
Operating Procedures (SOP) manual to assist providers during the study: 
 management of sexual partners  
 standards for good practice in partner notification 
 standard questions to assess partner risk  
2.2 Year 2 ‘Pee-in-a-pot’ screening studies in non-clinical settings 
Several non-clinical settings were explored as possible settings for outreach or 
community based screening, such as an army base, a prison, a hostel for asylum 
seekers, and an adolescent youth service. It was not feasible to proceed with screening 
in these sites for logistic reasons, and because of age issues in the youth service. 
Screening in non-clinical settings in higher education institutions (HEIs), i.e. through 
offering a ‘pee-in-a-pot’ (PIP) service during a suitable event, was explored and 
developed.  
Guided by the findings of the focus groups (See Background Studies:  Acceptability 
and Feasibility of Screening), and consultation with the Student Health Units in two 
HEIs, a one week screening program, called a ‘pee-in-a-pot’ event, was designed and 
planned. Each event was held during the annual sexual health awareness week which 
is a student organised event designed to promote positive sexual health in each of the 
HEIs.  
Planning and preparation 
Posters and information leaflets were used to help attract attention to the pilot and 
were distributed around each campus. Media releases, radio broadcasts, email alerts 
and newspaper articles were used to publicise the event. A poster competition was 
held inviting students to design a poster, image and slogan for the event (the winning 
poster is in Appendix I).  This was used throughout the event on all materials 
including volunteer t-shirts. 
Testing packs 
Testing packs (comprising small specimen bags containing a 10ml urine container, a 
pen and an information card) were designed for the study (Appendix J). Testing was 
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anonymous and each pack was identified through a unique code. Participants who 
chose to take a test were instructed to read the information leaflet, write their mobile 
number and date of birth on the urine container, urinate in the specimen container and 
keep the information card.  
Consent for testing was implied through the completion of details on the sample 
container. Specimen collection boxes were located inside toilet areas where 
participants were instructed to leave their samples in a sealed specimen bag. Testing 
packs were made available for three to four hours each day for 7 days in total between 
both sites. Project researchers collected the specimen bags and transported them to the 
laboratory services each day.  
Peer volunteers 
Student (peer) volunteers were recruited to distribute testing packs and information 
leaflets to potential participants on the two student campuses during the sexual health 
awareness and guidance (SHAG) week. Thirty five volunteers were recruited who 
were given training on chlamydia and the background to the research project. 
Volunteers were given a €25 voucher for their participation (approximately four hours 
each). Volunteers were dressed informally and were easily identified through cartoon 
t-shirts with ‘Pee-in-a-pot Volunteer’ printed on the back (Appendix K). 
Screening approach 
The approach used was adapted during the week to maximise privacy for participants. 
While testing packs were initially distributed in communal areas, as the event 
progressed male and female toilet areas became the focal point for distribution. Packs 
were left around sinks, mirrors and inside toilet cubicles, which led to more 
participants self-selecting for screening.  
The most common approach was for students to pick up a pack themselves in the 
toilet cubicle. Male volunteers were allocated to male bathrooms and other male 
oriented entertainment venues, such as pool and snooker rooms while female 
volunteers were allocated to female toilets and other communal areas.  
Results notification 
Positive results in non-clinical ‘pee-in-a-pot’ settings were communicated to the 
Student Health Unit doctors who contacted these persons directly by phone to 
organise treatment.  Those who tested negative received a standard text message from 
the Research Health Adviser (RHA).  
2.3 Interviews with screened participants  
Thirteen in-depth interviews were conducted with young adults who had undertaken 
screening (Appendix L: topic guide).   These consisted of seven interviews with ‘pee-
in-a-pot’ participants and six interviews with clinical setting attendees (GP, SHU and 
FPC). Respondents were recruited either by the RHA during a telephone liaison call 
or by the individual responding to student intranet advertisements for interview 
participants.  Non-directive semi-structured interviews were conducted to allow 
respondents to shape their own accounts. Interviews were tape-recorded (with 
respondents’ permission) and fully transcribed. The resulting data was coded and 
thematically analyzed by a public health specialist using NVivo revision 1.3 
(qualitative data analysis software).  
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2.4 Post pilot interviews with health care providers 
At the end of the pilot study, health care providers who took part in the pilot study 
were invited to participate in a semi-structured interview.  The purpose was to discuss 
providers’ experiences of the screening processes and explore their views and 
recommendations on the feasibility of rolling out a chlamydia screening programme 
in primary care settings.  
Three members of the research team who were healthcare professionals and 
experienced researchers conducted semi-structured individual face to face interviews. 
A topic guide was used based on the literature (Appendix L). Interviews were 
conducted at a time convenient to participants and all took place in participants’ place 
of work.  Interview questions were divided into sub-sections which included their 
experience of: offering the test, sampling, giving results, partner notification and 
perspectives on feasibility. In addition, overall attitudes to the process and 
recommendations for future programmes were also discussed. 
Interviews lasted from thirty to forty minutes and were digitally recorded and 
transcribed verbatim. Transcription was conducted by a professional transcriptionist 
who signed a confidentiality agreement. Transcripts were verified for accuracy by 
replaying tape recordings while reading transcripts.  
Participants were selected based on their screening activity during the pilot and also 
their geographical location. Twenty-one providers were approached with phone calls 
inviting them to take part in an interview. While no providers refused, four providers 
did not return phone calls. One provider was on maternity leave.  
Sixteen health care providers from general practices, family planning clinics and 
student health units were interviewed. One declined to have her voice recorded but 
still participated. Data saturation was judged to have occurred at sixteen interviews. 
Interviewees were directly involved in the screening pilot.  
We sought to achieve diversity in participants based on a number of factors: these 
included setting (family planning, student health, and general practice settings), urban 
or rural based services, and professional grouping (doctor or nurses). Nine general 
practitioners and seven practice nurses were interviewed, all of whom were female. 
While we were keen to capture a diverse gender perspective in this work our attempts 
to get male health care providers to participate in an interview were unsuccessful. We 
actively sought to capture the experiences and attitudes of health care professionals 
who had high, as well as low rates of testing during the chlamydia screening pilot. In 
addition, we were keen to capture the views of health care providers who were 
enthusiastic and also those who were less than enthusiastic about the screening 
process. 
Data analysis 
Two researchers from the research team were involved in reviewing transcripts and 
data analysis to ensure reliability. Thematic analysis was used to generate categories 
and themes related to the aims of the research. The researchers worked independently 
initially identified emerging themes and then together to decide on categories and 
finalise main themes.  
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2.5 Laboratory methods 
Qualitative interviews were conducted with staff from the Microbiology Department 
of Galway University Hospital where the Chlamydia trachomatis testing was 
conducted, after the screening pilot. Interviews were coded and thematically analyzed.    
Specimen management 
Specimens were frozen for batch testing.  The design and costs of the testing process 
meant that it was necessary to accumulate a sufficient number of specimens to form a 
batch for testing, particularly in the early stage of the pilot when recruitment was slow.  
Specimens were tested with Polymerase Chain Reaction (PCR) testing technology. 
The test used was the COBAS
®  
TaqMan
® 
CT Test v2.0 manufactured by Roche 
Diagnostics, Switzerland.  
Management of test result  
Electronic and paper copies of test results were sent by the Microbiology Department 
to the screening sites. A copy of test results was also sent to a medical doctor in the 
research team to allow for patient follow-up by the RHA. 
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3. Results 
3.1 Overview of Screening Results 
The screening intervention commenced in September 2008 and was completed in 
April 2009.  Screening was conducted in three different types of clinical settings (GP, 
SHU (Student Health Units) and FPC (Family Planning Clinics), and in one type of 
non-clinical setting (two HEIs) where two one week ‘pee in a pot’ (PIP) screening 
interventions took place. 
Participation rates 
During the pilot 1112 participants were screened: of these 114 (10%) were excluded 
from analysis: 
 83 were outside the eligible age range (15 were aged less than 18 years, 58 
were aged 30 years or older) and eight had no age given 
 23 were excluded because of mislabelling or inadequate identifiers on the 
specimen container. 
Offer rates 
Accurate information on offer rates is not available as the total number of people 
offered screening was not recorded by any provider due to time constraints.  Clinical 
settings reported that up to 30% of eligible people attending clinical settings were 
offered a screening test for chlamydia.  
However, on detailed examination of records from four general practice settings 
where computerised patient databases were in place, the offer rates ranged from 0.9 - 
3% for male attendees and from 2 - 9% for female attendees (refusal rates were 
utilised). For the two SHUs, the offer rates ranged from 0.08 - 1.3% for male 
attendees and from 0.3 - 2.8% for female attendees. The FPC did not have the 
information system required to facilitate do this assessment.   
Refusals 
Providers in the clinical settings were requested to record refusals to participate. The 
total number of participants offered screening was not recorded by most providers due 
to time pressures. Nineteen providers recorded 94 refusals (65 female and 29 males) 
giving a minimum refusal rate of 7.8%. Interviews with providers estimated that less 
than 10% of those offered a screen in general practices declined, 33% in SHU, and 
20% in FPC.  
3.1.1 Study population screened 
The study population consisted of 998 eligible persons: 460 in clinical settings (286 
GP, 100 SHU and 74 FPC) and 538 (54% of those screened) in non-clinical PIP 
settings. Of those screened in clinical settings, 29% took place in general practices. 
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Table 1. Numbers of screened people by settings (percentages out of total n=998)  
Setting GP 
n(%) 
SHU 
n(%) 
FPC 
n(%) 
PIP 
n(%) 
Total 
n(%) 
Total 
 
286 (28.7) 100 (10) 74 (7.4) 538 (53.9) 998 (100) 
Tables 1 and 2 summarise the demographic characteristics of population screened.  Of 
the 998 participants, 726 (73%) were women, 248 (25%) were men. Sex was not 
recorded on 23 (2.3%) persons screened. 
Table 2. Description of eligible people screened during the pilot  
(percentages out of total n=998) 
Age Female 
n(%) 
Male 
n(%) 
Sex not 
specified 
n(%) 
Total 
n(%) 
18-19 
 
137 (13.7) 63 (6.3) 2 (0.2) 202 (20.2) 
20-24 
 
398 (39.9) 139 (13.9) 12 (.2) 549 (55) 
25-29 
 
192 (19.2) 46 (4.6) 9 (0.9) 247 (24.7) 
Total 727 (72.8) 248 (24.8) 23 (2.3) 998 (100) 
 
The mean age of participants was 22.3 years (median: 21).  In females the mean age 
was 22.4 years (median: 22, and among males the mean age was 21.6 years (median: 
21). Table 3 describes the ages of participants in the different settings.   
Table 3. Mean and median ages (years) by settings 
Setting 
(range 18-29) 
GP 
 
SHU 
 
FPC 
 
PIP 
 
Mean age  
 
24.3 21.3 24.4 21 
Median age  
 
24.5 21 25 21 
3.1.2 Screening Processes   
Table 4 summarises the types and distribution of specimens by sex taken in each 
setting: 878 (91%) were urines and 97 (9.7%) were cervical swabs. 
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Table 4. Specimen type taken by settings (percentages out of total n=998) 
 Urine 
 
Cervical  
Setting Female 
n(%) 
Male 
n(%) 
Sex not 
specified 
n(%) 
Female only 
n(%) 
Totals 
N(%) 
GP 
 
164 (16.4) 35 (3.5) 10 (1.0) 77 (7.7) 286 (28.6) 
SHU 
 
79 (7.9 ) 18 (1.8) 1 (0.1) 2 (0.2) 100 (10.0) 
FPC 
 
51 (5.1) 4 (0.4) 1 (0.1) 18 (1.8) 74 (7.4) 
Total  
(clinical  
settings) 
 
294 (29.5) 
 
57 (5.7) 
 
12 (1.2) 
 
97 (9.7) 
 
460 (46.1) 
PIP 
 
336 (33.6) 191 (19.1) 11 (1.1) 0 538 (53.9) 
Total 
 
 
630 (63) 248 (24.8 ) 23 (2.3) 97 (9.7) 998 (100)* 
*Percentages may not add up to 100% due to rounding  
Table 5 describes the ages of those who had cervical swabs taken in clinical settings. 
Among the 97 cervical swabs processed, 29 (29.9%) were taken from participants 
who were outside the 25-60 years recommended age interval for cervical smears. The 
majority of these were done in general practice. 
Table 5. Cervical swabs by age group and clinical setting 
Age group 
GP 
n(%) 
SHU 
n(%) 
FPC 
n(%) 
Total 
n(%) 
18-19 1 (1.0) 0 1 (1.0) 2 (1.0) 
20-24 26 (26.8) 1 (1.0) 0 27 (27.8) 
25-29 50 (51.5) 1 (1.0) 17 (17.5) 68 (70.1) 
   Total 
77 (79.3) 2 (2.0) 18 (18.5) 97 (100) 
Table 6 shows that doctors and practice nurses took equivalent numbers of cervical 
swabs. In general practice settings, doctors took the majority of specimens. In student 
health units (SHUs) and in the family planning clinic practice nurses took over 90% 
of the specimens: in these settings, the majority of patients were triaged by the nurses 
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and where necessary referred to the doctor. Patients could also make appointments 
directly with the doctor if they wished.  
Table 6. Specimen taker by clinical settings (percentages 100% in each column)  
 
Specimen 
 taker 
 
 
GP 
(n%) 
 
FPC 
(n%) 
 
SHU 
(n%) 
 
Total 
Urine Cervical Urine Cervical Urine Cervical 
Doctor 
 
159 (76.0 ) 44 
( 57.1) 
3 (5.3) 3 (16.6) 1 (1.0 ) 0 210 (45.6) 
Nurse 
 
40 (19.1) 32 (41.5) 52 (92.8) 15 (83.3 97 (98.9) 2 (100) 238 (51.7 
Missing  
(taker ) 
 
10 (4.7) 1 (1.2 ) 1 (1.7) 0 0 0 12 (2.6) 
Total  
 
209 (100) 77 (100) 56 (100) 18 (100) 98 (100 ) 2 (100 ) 460 (100) 
The median time for both the doctor and nurse to obtain a urine test was 5 minutes. 
The median time to take a cervical swab was 5 minutes for a practice nurse and 7 
minutes for a doctor. Table 7 demonstrates there were similarities in the time required 
for completing a test between the settings.  
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Table 7. Time to take test in clinical settings (in minutes) 
 
Setting 
 
Time to take test (in minutes) 
GP  (n=252, 34 missing) 
 Range 2-20 
 Mean 6.8 
 Median 5 
  
SHU (n=77, 23 missing) 
Range 4-15 
Mean 7.2 
Median 5 
  
FPC  (n=60, 14 missing) 
Range 4-15 
Mean 5.6 
Median 5 
  
Total settings (n=389, 61 missing) 
Range 2-20 
Mean 6.7 
Median 5 
Interval from test date to result date (in weeks) 
The mean interval from testing to reporting of results was 4.97 weeks (median =5).  
For a small proportion of tests (7.4%), the interval was longer than 8 weeks.  Urine 
samples were the main specimen type requested during the pilot study. However, the 
routine tests for chlamydia in the laboratory used in the pilot study are vaginal, 
cervical and urethral swabs. Routine clinical specimens are reported within a week of 
submission in almost all cases. 
Efficient processing of urine samples within the financial constraints of the study 
meant that it was necessary to accumulate a sufficient number of urine specimens to 
form a large enough batch for testing. The issues in relation to the turnaround time 
and specimen type for this project are entirely related to the practical difficulties of 
accommodating the extra work of a once–off research project at the lowest practical 
cost within a laboratory that was not specifically set up for the purpose and which did 
not have any spare capacity. This is not likely to be an issue in the context of an 
ongoing screening programme with a structured and resourced laboratory service 
component.   
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3.1.3 Screening in clinical settings 
Overall, 286 persons (240 females, 35 males and 11 sex not specified) were screened 
in general practices. One hundred persons (81 females, 18 males and 1 sex not 
specified) were screened in two SHUs, and 74 (70 female and 4 males) were screened 
in the FPC. 
General practices  
Out of the original 29 general practices recruited, 23 provided specimens for testing. 
The results from these 23 general practices were included in the analysis.  The mean 
number of specimens (urine and cervical swab) per general practice was 12.4 (range: 
1-61) median=6.  Table 8 summarises the profile of participating general practices.  
Table 8. Profile of general practices in screening programme 
  *Type of practice 
 
n=23 
Group practices (>1 GP) 
 
18 
Single-handed general practices 
 
5 
Training general practices 
 
6 
General practices with practice nurse (s) 
 
16 
Rural based general practices   
 
10 
Urban based general practices  
 
13 
*These are non-exclusive categories 
The mean number of cases screened was higher in urban practices (15.8 vs. 6.2); 
group practices (14.7 vs. 4.4) and in training practices (17.8 vs. 10.5).  Practices with 
or without a practice nurse screened the same mean number of participants (12.4). 
Four practices screened more than 20 people: these were urban group practices with a 
female clinician who was providing sexual and reproductive health services.  Table 9 
summarises screening by different participating practices. 
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Table 9. Specimen type by practice type (percentages by row) 
 
Practice type* 
Cervical 
n(%) 
Urine 
n(%) 
Total specimens 
n(%) 
 
Group practice Yes 76 (28.7) 188 (71.2) 264 (100) 
No 1 (4.5) 21 (95.4) 22 (100) 
Training practice Yes 23 (21.4) 84 (78.5) 107 (100) 
No 54 (30.1) 125 (69.8) 179 (100) 
Practice nurse Yes 49 (24.6) 150 (75.3) 199 (100) 
No 28 (32.1) 59 (67.8) 87 (100) 
 
Urban general practice 
 
 
64 (31.2 ) 
 
141 (68.7) 
 
205 (100) 
 
Rural general practice  
 
 
13 ( 16 ) 
 
68 (84 ) 
 
81 (100) 
*These are not exclusive categories 
Between two thirds and three quarters of tests were urine tests, across all types of 
practices. 
3.2 Risk factors of population screened in clinical settings 
Risk factor data were collected only from those screened in clinical settings, i.e. not at 
the ‘pee-in-a-pot’ events, where students were not requested to complete this form. 
19 
Table 10. Risk factors of study population in clinical settings and the Relative 
Risk for each risk factor, male versus female.  (Percentages by column based on 
total respondents to each question)* 
Risk factor 
 
Female 
n(%) 
Male 
n(%) 
Relative Risk for 
each risk factor 
(male vs. female) 
(95% CI) 
Number of sex partners    
1 57 (16.5) 3 (6) 1 
2-4 120 (34.8) 12 (24) 1.18 (0.90, 1.55) 
5-14 142 (41.2)  20 (40) 2.47 (0.76, 8.01) 
>14 25 (7.2) 15 (30 ) 4.13 (2.34, 7.28) 
New partner in past 3 months    
Yes 134 (38.1 ) 31 (60.7) 1.59 (1.23, 2.06) 
No 217 (61.8 ) 20 (39.2 )  
Two or more partners in past year    
Yes 126 (35.6 ) 29 (56.8 ) 2.37 (1.26, 4.49) 
No 227 (64.3 ) 22 (43.1 )  
Unusual discharge    
Yes 49 (13.8 ) 4 (7.8 ) 0.57 (0.21, 1.51) 
No 306 (86.1) 47 (92.1)  
Pain on passing urine    
Yes 38 (10.7) 13 (25.4) 2.37 (1.36, 4.13) 
No 315 (89.2 ) 38 (74.5)  
    
*The sum of the categories for each determinant varies slightly because of missing data. 
The mean number of life time sex partners was 6.7 (range: 0-60, median = 5).  In this 
population 38.1% of women and 60.7% of men reported having a new sex partner in 
the three months before the test, and 35.6% of women and 56.8% of men reported 
having more than 2 sexual partners in the previous year. Males were significantly 
more likely than females to have had high numbers of sex partners, a new partner in 
the last 3 months and more that two partners in the last year. In the screened 
population 13.8% of women and 7.8% of men reported an unusual discharge. Males 
were significantly more likely to have dysuria (pain on passing urine) (10.7% of 
women and 25.4% of men).  
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3.3 Screening in non-clinical settings 
During the 6.5 ‘pee-in-a-pot’ (PIP) days 592 urine tests were collected (mean 91 per 
day). Of these 54 (9%) were excluded from analysis because: 
 45 were outside the eligible age range (9 were aged less than 18 years, 21 were 
aged 30 years or older) 
 9 had labelling errors. 
There were 538 samples eligible for analysis.  Table 11 summarises demographic 
characteristics of those screened in non-clinical settings.  
Table 11. Description of participants in non-clinical setting (PIP)  
     (percentages out of n=538) 
Age 
 
Female 
n(%) 
Male 
n(%) 
Unknown sex 
n(%) 
Total 
n(%) 
18-19 
 
93 (17.2) 56 (10.4 ) 1 (0.1) 150 (27.8 ) 
20-24 
 
214 (39.7 ) 112 (20.8 ) 9 (0.1 ) 335 (62.2) 
25-29 
 
29 (5.3) 23 (4.2) 1 (0.1) 53 (9.8) 
Total 
 
336 (62.4) 191 (35.5) 11 (2.0 ) 538 (100) 
3.4 Management of positive persons 
3.4.1 Positivity rates 
Of the 998 people screened 48 (4.8%, 95% Confidence Interval (CI) 3.5-6.1) tested 
positive. The positivity rate was 4.8% (95% CI 3.3-6.3) in females, and was 5.2% 
(95% CI 2.5-8.0) in males. 
Of the 460 eligible people screened in clinical settings, 27 (5.9%, 95% CI 3.7-8.0) 
tested positive. Of the 538 persons screened in the non-clinical settings 21 (3.9%, 
95% CI 2.3-5.5) tested positive.  The following tables provide a breakdown of results 
by clinical and non-clinical setting (Table 12), age bands (Table 13) and sex and 
specific settings (Table 14). 
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Table 12. Chlamydia results by sex in clinical and non-clinical settings. 
 Clinical Non-clinical 
  
CT neg 
n(%) 
 
CT pos 
n(%) 
 
Total 
clinical 
 
CT neg 
n(%) 
 
CT pos 
n(%) 
 
Total 
non-clinical 
Female  373 (95.4) 
 
18 (4.6 ) 391 (100) 319 (95) 17  (5.0) 336 (100) 
 
Male  48 (84.2) 
 
9 (15.8) 57 (100) 187 (97.9) 4  (2.1) 191 (100) 
 
Sex not 
specified 
12 (100) 0 12 (100) 
 
11 (100) 0 11 (100) 
 
Total 
 
433 (94.1 ) 27 (5.9) 460 (100) 517 (96.1) 21 (3.9) 538(100) 
The positivity rate for females in clinical settings (4.6%) was not statistically 
significantly different to females in non clinical settings (5.0%); whereas for males the 
rate of positivity in clinical setting (15.8%) was significantly higher than in non-
clinical PIP settings (2.1%), Odds Ratio: 8.77 (95% CI 2.33-35.5).  Males attending 
clinical settings were also more likely to be CT positive than females attending 
clinical settings, Relative Risk: 3.43 (95% CI 1.62-7.26).  This difference was 
statistically significant.   
Chlamydia trachomatis (CT) positivity rates were similar across the three age bands, 
with no statistically significant differences between age groups (Table 13). 
Table 13. CT results by age bands in clinical and non-clinical settings    
(Percentage by age band in clinical and non clinical settings) 
 Clinical Non-clinical 
 
Years 
 
CT neg 
n(%) 
 
CT pos 
n(%) 
 
Total 
clinical 
 
CT neg 
n(%) 
 
CT pos 
n(%) 
 
Total 
non-clinical 
18-19 49 (94.2) 3 (5.8) 52 (100) 145 (96.6) 5 (3.4) 150 (100) 
 
20-24 202 (94.4) 12 (5.6) 214 (100) 319 (95.2) 16 (4.8) 335 (100) 
 
25-29 
  
182 (93.8) 12 (6.2) 194 (100) 53 (100) 0 53  (100) 
Total 
 
433 (94.1) 27 (5.9) 460 (100) 517 (96.1) 21 (3.9) 538 (100) 
Positive male cases were found in both GP and SHU settings (Table 14).  Men were 
not screened at the FPCs. 
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Table 14. CT results by sex within clinical settings 
 GP SHU FPC 
 CT 
neg 
(%) 
CT 
pos 
(%) 
 
GP 
Total 
(%) 
CT 
neg 
(%) 
CT 
pos 
(%) 
 
SHU 
Total 
(%) 
CT 
neg 
(%) 
CT 
pos 
(%) 
 
FPC 
Total 
(%) 
Female 229 
(95) 
12 
(5) 
241  
(100) 
 
80 
(98.8) 
1 
(1.2) 
81 
(100) 
64 
(92.8) 
5 
(7.2) 
69 
(100) 
Male 30 
(85.7) 
5 
(14.3) 
35 
(100) 
14 
(77.8) 
4 
(22.2) 
 
18 
(100) 
4 
(100) 
0 4 
(100) 
Sex not 
specified 
 
10 
(100) 
0 10 
(100) 
1 
(100) 
0 1 
(100) 
1 
(100) 
0 1 
(100) 
Total 
 
 
269 
(93.4) 
17 
(5.9) 
288 
(100) 
95 
(95) 
5 
(5) 
100 
(100) 
69 
(9.3) 
5 
(6.7) 
74 
(100) 
3.4.2 Risk factors 
Table 15 shows the risk factors of those screened and among those who tested 
positive, in clinical settings only.  None of the sexual behaviour or symptom risk 
factors reached statistical significance for CT positivity among those attending 
clinical settings.   
There were no significant differences between males and females in respect to 
associations of risk factors and test results. 
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Table 15. Positive test according to sexual behaviour and symptoms in men and 
women attending clinical settings  
Variable      No. of   
participants 
No. of 
 positive cases 
(%) 
Crude OR  
(95% CI) 
Total partners    
1 61 1 (16.4) 1 
2-4 132 9 (6.8) 4.4 (0.6, 94.6) 
5-9 113 6 (5.3) 3.4 (0.4, 75.9) 
10 or more 90 6 (6.7) 4.1 (0.5, 91.8) 
New partner in last 3 
months 
   
No 239 13 (5.4) 1 
Yes 166 9 (5.4) 1.0 (0.4, 2.6) 
    
Two or more partners in last 
year 
   
No 251   9 (3.4) 1 
Yes 156 13 (8.3) 2.4 (0.9, 6.6) 
    
Discharge    
No 357 20 (5.6) 1 
Yes 53 2 (3.8) 0.7 (0.1, 3.1) 
    
Pain on passing urine    
No 356 18 (5.1) 1 
Yes  51 4 (7.8) 1.6 (0.4, 5.3) 
The numbers in categories varies due to missing data/non-response. 
Of the two risk factors routinely used as risk indicators, only two or more partners in 
the previous year was a potentially useful discriminator, with a crude odds ratio (OR) 
of 2.2 (95%CI: 0.9-6.6).  The lower CI is very close to 1 and would be worth 
exploring with a larger sample size.  There was the same positivity rate of 5.4% 
whether or not the case had reported a new partner in the previous three months. 
show the risk factors among those persons who tested positive by sex. 
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Table 16. Risk factors for males in clinical settings by CT result 
Risk factors for males in clinical 
settings 
Negative cases 
n(%) 
Positive cases 
n(%) 
Number sex partners 
1 3 (6.2) 0 
2-4 9 (18.8) 3 (33.3) 
5-9 8 (16.7) 1 (11.1) 
10 or more 22 (45.8) 4 (44.4) 
Non-response (missing) 6 (12.5) 1 (11.1) 
Total  48 9 
New partner in past 3 months 
Yes 27 (56.3) 4 (44.4) 
No 16 (33.3) 4 (44.4) 
Non-response (missing) 5 (10.4) 1 (11.1) 
Total 48 9 
>2 partners in past 12 months 
Yes 24 (50)  5 (55.6) 
No 19 (39.6) 3 (33.3) 
Non-response (missing) 5 (10.4) 1 (11.1) 
Total 48 9 
Pain on passing urine 
Yes 10 (20.8)  3 (33.3) 
No 33 (68.8) 5 (55.6) 
Non-response 5 (10.4) 1 (11.1) 
Total 48 9 
Unusual discharge 
Yes 4 (8.3)  0 
No 39 (31.2) 8 (88.9) 
Non-response 5 (10.4) 1 (11.1) 
Total 48 9 
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Table 17. Risk factors for females in clinical settings by CT result  
Risk factors for females in clinical 
settings 
Negative cases 
n(%) 
Positive cases 
n(%) 
Number sex partners 
1 56 (15) 1 (5.6) 
2-4 114 (30.6) 6 (33.3) 
5-9 99 (26.5) 5 (27.8) 
10 or more 61 (16.6) 2 (11.1) 
Non-response (missing) 43 (11.5) 4 (22.2) 
Total  373 18 
New partner in past 3 months 
Yes 129 (34.6) 5 (27.8) 
No 208 (55.8) 9 (50) 
Non-response (missing) 36 (9.7) 4 (22.2) 
Total 373 18 
>2 partners in past 12 months 
Yes 118 (31.6) 8 (44.4) 
No 221 (59.2) 6 (33.3) 
Non-response (missing) 34 (9.1) 4 (22.2) 
Total 373 18 
Pain on passing urine 
Yes 37 (9.9) 1 (5.6) 
No 302 (81) 13 (72.2) 
Non-response (missing) 34 (9.1) 4 (22.2) 
Total 373 18 
Unusual discharge 
Yes 47 (12.6) 2 (11.1) 
No 294 (78.8) 12 (66.7) 
Non-response ( missing) 32 (8.6) 4 (22.2) 
Total 373 18 
3.4.3 Treatment of positive persons 
Forty five (94%) of the 48 CT positive cases were successfully treated. Forty 
(89%) received a single oral dose of azithromycin 1g, doxycyline and 
erythromycin were used to treat two additional positive cases, and the treatment 
type was unknown for three cases where the location of treatment was abroad. 
Three cases (6.2%) were not contactable and therefore (presumably) not treated for 
chlamydia.      
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Table 18. Location of treatment of positive persons summarises those screened in 
non-clinical settings who attended their GP and /or student heath units for treatment.  
Table 18. Location of treatment of positive persons 
Setting 
 
Females treated 
n(%) 
Males treated 
n(%) 
Total 
n(%) 
GP 13 (27.0) 5 (10.4) 18 (37.5 ) 
SHU 13 (26.5) 8 (16.6) 21 (43.7) 
FPC 4 (8.3 ) 0 4 (8.3) 
GUM 1 (2.0) 0 1 (2.0) 
GUM (UK) 1 (2.0) 0 1 (2.0) 
Total treated 32 (91.4) 13 (100) 45 (93.8) 
Not contactable  3 (6.2) 0 3 ( 6.2) 
Total 35 (72.9) 13 (27.0) 48 (100) 
3.4.4 Further STI Testing 
Twenty-five (52.1%) positive cases are known to have had further STI testing. Eleven 
were tested in general practice, where a range of STI tests were performed, while 
thirteen were tested in GUM clinics. The testing location was unknown for one case. 
All tested negative for other STIs. Table 19. Outcomes and location of further STI 
testing/screening on positive cases gives details of these tests. 
Four positive cases refused further STI testing.  Fifteen did not attend for screening despite some 
receiving appointment details and all indicating they would attend. 
Table 19. Outcomes and location of further STI testing/screening on positive 
cases 
Outcomes 
 
CT pos 
Female 
n 
CT pos 
Male 
n 
CT pos 
Total 
n(%) 
Location of STI testing    
GP 7 4 11 (44) 
SHU  0 0 0 
FPC 0 0 0 
GUM clinics 9 4 13 (52) 
Location of further STI testing unknown 1 0 1 (4) 
Total tested 17 8 25 (100) 
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3.4.5 Retests outcomes  
All clinical settings offered retest facilities (with urine sampling).  Those who did 
attend for retesting attended their place of original consultation (GP/FPC/ SHU). 
Table 20 summarises the retest outcomes in clinical and PIP settings. 
The RHA contacted by phone 24 positive cases who had been detected in clinical 
settings and fourteen positive cases detected at the PIP events. The remainder had 
either not given consent or were not contactable. Nineteen (48.7% of those contacted) 
were retested and all retest results were negative for chlamydia. 
All the PIP positive patients were referred to attend the GUM clinic for their retest 
(endocervical/urethral swab).  Urine testing for the study was no longer available at 
this time as the urine testing service was provided for a defined period, which had 
expired. None of the PIP patients attended the GUM clinic for their retest despite five 
having appointments made for them.  
Table 20. Retest outcomes in clinical and non-clinical settings 
Clinical settings n(%) 
 
PIP* n(%) 
 
Attended & retested 
 
19 (66.6) 
 
Attended 
 
0 
 
Did not attend  
(after being contacted by RHA) 
 
5 (18.5) 
 
Did not attend  
(5 appoint. made by RHA) 
 
11 (52.3 
Failure to contact∞  
(on retest phone call)   
2 (7.4) Failure to contact 
Not contactable†  
3 (14.2) 
3 (14.2) 
 
Case not at risk of re-infection  
 
1 (3.7) 
 
No consent to contact 
 
1 (4.7 ) 
   
Declined retest 
 
3 (14.2) 
 
Total 
 
27 (100) 
  
21 (100) 
*Urine testing was not available to PIP CT positives for retest. 
†Non- contactable: no contact number for participant 
∞Failure to contact: unable to contact participant after several attempts. 
3.4.6 Partner notification  
Figure 3 summarises the results of partner notification.  Partner notification was not 
carried out on five of the 48 positive cases:  
 One patient did not consent to be referred to the health adviser.  The doctor 
who managed the case conducted initial partner notification discussions with 
the patient. However, outcomes were not monitored  
 One index case refused partner notification with no follow up on partners. 
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 Three positive cases were non-contactable.  
Of the remaining 43 index cases, the RHA discussed and followed up partner 
notification with 25 (58.1%). A practice nurse from one of the student health units 
discussed partner notification with 11 cases (25.6%); practice nurses from the family 
planning clinics took on this role with five cases (11.6%).  Partner notification for two 
cases (4.6%) was done at the local GUM clinic.  
The preferred method of notification was patient referral where the index case notified 
previous and current partners themselves.  83% (46) of notifications were undertaken 
by the index case (patient referral) and 17% (10) where undertaken by the research 
heath adviser (provider referral). In addition the RHA did a follow-up call to all 
consented index cases.   
Use of community contact cards  
Thirty four contact cards were distributed by the health care providers in primary care 
and only four cards were returned, which were collected from partners at the 
following settings:  GUM clinic (2), student health unit (1) and general practice (1).  
Partner Contact 
Overall 68 partners were reported by the 43 index (positive) cases.   Fifty six (82.3% 
of) partners were contacted by either the index cases or health care providers and 
informed of their potential exposure to chlamydia.  Figure 4 summarises the outcomes 
Ten partners were not contactable as the index (positive) case had no contact details 
because these were casual partners. Despite contact details being provided and several 
attempts being made, two contacts were not contactable.  
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 68 (100 %)
Total partners reported
 
56 (82.3%)
Partners contacted
37 (66%)
Partners treated
12 (17.6%)
Partners not contactable 
12  
tested & treated 
confirmed
10 
treated 
confirmed
1
tested & treated 
unconfirmed
27
treated 
unconfirmed
6 (11%)
Treatment outcome
 unknown
13 (23%)
Partners tested & treated
43 index cases who 
provided partner 
information
48 index 
cases 
 3 non-contactable
 1 refusal of PN
 1 not consented for follow-up
 
Figure 3. Partner outcomes 
Overall 0.3 contacts were screened per contactable index case in the study (clinician 
confirmed). This and other performance measures for partner management are shown 
in Table 21. Performance measures for partner management. 
Table 21. Performance measures for partner management  
Published Targets 
 
Pilot Study 
 
NCSP: within 90 days of the first partner notification discussion, at least 
0.6 partners are to be verified as treated per index case∞ [9] 
 
 
0.5 
BASSH guidelines and targets: 0.64 contacts are screened per index case 
for chlamydia (for clinics not in large cities ∞) [7] 
 
0.3 
  
Measures with no targets set†:  
Partners treated per index case (clinician confirmed and non-confirmed) 1.1 
Partner contact rate 82.3% 
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Partner treatment rate 73.5% 
Effective partner treatment rate* 89.3% 
Effective partner testing rate* 23.2% 
∞Except in London or a large city where the standard is 0.4. In this study, the denominator for index cases is 45 
(i.e. The number of contactable index cases) 
† The NSCP Annual Report 2004-5 described these effectiveness measures of partner notification based on their  
findings (these are not clinical standards). 
* Effective rate uses number of contacted partners (n=56) as denominator. 
Note: Unconfirmed indicates reported by the index case. 
Treatment outcomes for partners 
Treatment outcomes for twenty-eight partners were confirmed by the index cases 
(‘unconfirmed’) and for twenty-two partners, treatment was confirmed by a clinician 
in the settings (doctor or nurse).   
Treatment location 
Overall, 29 (51.7%) partners were treated in clinical settings with the remaining 27 
(48.3%) treated in GUM settings or in other unknown locations.  In GUM settings, 
treatment was confirmed by a health care professional for seven partners with 
treatment confirmed by the index case in the remaining 7 partners. 
The majority of partners within clinical settings (n=22, 40%) were treated in general 
practice, four (7.2%) were treated in student health units and three (5.4%) were 
treated in the family planning clinic. Most partner treatments were confirmed by the 
index cases (see figure 5 for further details).  In total, 13 health care providers 
confirmed partner treatment in primary care. 
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Partner treatment 
location
56
22 (40%)
general practice 
14 (25.4%)
Gum clinics
3 (5.4%)
family planning 
clinic
13 (27.9%)
location unknown
7
 confirmed
15 
unconfirmed
3
confirmed
Primary care settings
29( 51.7%)
Other
27( 48.3%)
4 (7.2%)
student health unit
1 
unconfirmed
3
 confirmed
7 
confirmed
7 
unconfirmed  
Figure 4. Treatment location of partners 
3.5 Interviews with screened participants 
This section relates to the thirteen interviews conducted with young adults who had 
participated in the screening pilot.  These consisted of seven interviews with PIP 
participants and six with clinical setting attendees (FPC, SHU and general practice).  
The clinical setting attendees included two male students (who attended SHUs) with 
positive results and four females with positive results: two from general practice 
settings, one from a family planning clinic and one from a student health unit.   
3.5.1 Reasons for accepting the screening offer in clinical settings 
For many participants, reasons for accepting the screening offer were multifactorial. 
These included the following; 
1. ‘Curiosity’ with some participants detailing no past experience of chlamydia 
screening and were willing to try it. 
2. ‘Needed it’. Some participants knew that they were potentially at risk for an STI 
due to a personal risk factor e.g. having had unprotected intercourse or change 
of partner.  Thus when the opportunity of the test arose, they were happy to take 
it ‘I reckoned I needed it and when the opportunity came up I took it’. 
3. ‘Free so why not?’  In the study the test and treatment was free for participants.  
During the narratives, several participants reiterated this was a major incentive 
in accepting the screening offer.  Participants felt a maximum cost of €25 would 
probably be acceptable in a future screening programme. However, felt they 
were much more likely to get screened if the testing was free. 
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4. Confidentiality of the screening process.  The whole process of screening was 
regarded as ‘confidential’. 
5. ‘For a laugh’ - A minority of participants viewed the screening process in a 
lighted manner and they were happy to participate in the pilot. 
6. It was a simple urine test. Participants were pleased with the urine testing as it 
was perceived as a ‘straight forward’ process with minimal effort involved.   
Some expressed no particular reason for accepting the screening offer. 
Knowledge of chlamydia 
Most knew about chlamydia but learnt more from the screening experience. 
Attitude to STIs 
There was generally a negative attitude towards STIs with most describing them as an 
embarrassing subject with associated stigma and taboo. 
History of past STI testing 
Very few interviewees reported a previous STI test.  Reasons for not having a STI test 
were discussed and were multi-factorial.  A minority of interviewees described feeling 
‘invincible’ and distanced themselves from the likelihood of having an STI.  Some 
described themselves as being ‘naïve’ and just not perceiving themselves to be at risk.   
Several participants were concerned about the perceived painful and invasive nature 
of STI testing.  A common concern for many was being seen in the waiting room of a 
GUM clinic which was a deterrent for attending the clinic.  
Views on charging for screening 
While participants mentioned a cost of up to €25 which would probably be acceptable, 
they were much more likely to get screened if the testing was free. 
Views on urine test 
All relevant participants were very happy with the urine test, because it was a simple, 
non-invasive and private test.  Other advantage of the urine test for participants was 
that the urine test was perceived to be ‘quick’ and participants could do the test 
themselves. 
Prior to screening, participants were anxious that the test could be invasive and this 
was of particular concern if a health care worker (HCW) of the opposite sex was 
offering the test.  The urine test was considered by participants as a “private” test and 
thus resolved this issue.  
Participant’s views on endocervical swab test 
Only one interviewee had the swab test.  She was having a cervical smear test done so 
had no problem with the swab; 
3.5.2 Participant’s views on clinical settings 
SHUs 
Opinions were very positive regarding this setting for STI testing.  It was described as 
a nice environment with friendly, relaxed staff who explained procedures well.  
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GP Setting 
Positive comments were made regarding the interaction with health care workers in 
this setting during the study- this included the management of the positive cases.  Two 
interviewees would not have attended their family doctor for screening due to family 
connection and close proximity in the local community.   
FPC Setting 
Positive comments were made regarding screening and the aftercare provided by the 
HCWs here.  The FPC was considered an easier setting in which to access STI testing, 
because the offer of a STI test fits with the context of a sexual health consultation or 
with a request for contraceptives. 
GUM clinic  
(Of note since these interviews were recorded, the main GUM clinic involved in this 
pilot has moved to a new purpose-built building with a larger waiting room). 
GUM clinics appear to generate negative connotations for interviewees.  One 
interviewee who had not attended any GUM clinic perceived that attending would 
make one feel “dirty”; that the clinic is “horrible” and she “would never want to go 
there”. 
Some interviewees described being concerned before attending the GUM clinic- their 
concerns centred on: the physical examinations they might be requested to undergo; 
the confidentiality of the clinic process and the potential to be seen at the clinic by 
someone they knew.  
One attendee described attending the GUM clinic as the worst part of the screening 
process as it was a ‘public’ experience.  Comments were repeatedly expressed by 
other attendees that attending the GUM clinic was ‘unnerving’, ‘formal’ and 
‘embarrassing’. 
In contrast, one participant was relaxed regarding the GUM clinic and whether or not 
she was seen by an acquaintance.  However this person described herself as being 
‘different’ to her friends (who would be anxious about attending). 
Impressions of the GUM clinic waiting room were generally negative.  It was 
considered not like an ordinary doctor’s waiting room; ‘awkward’ as very small in 
size and other attendees were embarrassed and ‘hiding behind newspapers’.  This was 
considered to reflect the ‘stigma’ of STIs. 
However one respondent (the same one who was relaxed about the GUM clinic) 
thought the waiting room was fine with a mixture of backgrounds and ages of 
attendees.  
The care provided by health care workers in the GUM clinic was considered 
professional and to a high standard.  It was noted that the doctors appeared under 
pressure which added to more formal atmosphere.  The SHUs were considered by 
student interviewees more positively as these were more ‘relaxed’ settings. 
Suggestions on improving GUM clinic: 
These included increasing the size of the waiting room; providing more reading 
materials and making attending more private.  This lack of privacy was considered a 
deterrent to attending.  
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3.5.3 Perspectives on health care workers characteristics 
Sex of health care worker 
There was a mixture of opinions on whether a health care worker of same sex was 
preferred.  One male respondent described initial anxiety that the health care worker 
might be female- this was allayed when he realised that only a urine test was required. 
Age of health care workers 
A mixture of opinions were again expressed with some preferring a younger health 
care worker who might relate more to their experiences; while others did not care 
what age the health care worker was. 
Health care worker profession preference  
No preference was voiced for nurse or doctor. 
Perspectives on role of the research health adviser 
Participants who had contact with the research health adviser/nurse were all very 
positive about this interaction.  She fulfilled several functions for the positive cases; 
these included: 
 Normalising the diagnosis and treatment for positive cases 
 Explaining and providing information 
 Reassuring and providing continued support 
 Guiding on partner notification and supporting in this process. 
Impact of chlamydia diagnosis on positive cases 
Initial impact of diagnosis: 
There was an initial negative impact on most cases- describing themselves as being 
shocked; feeling ‘dirty’, ‘horrible’, ‘down’, ‘upset’, ‘embarrassed’, ‘disbelief’, 
‘ashamed’ and with lowered self-esteem.  Some were annoyed with self or with 
partner.  Worries were expressed regarding future fertility and discomfort was 
described at not knowing that they were infected –‘That would be the strangest thing, 
obviously when you have some sort of an infection, disease or whatever it is, and not 
knowing about it, obviously you're carrying it.., it's off-putting’.  Some were relieved 
to have the infection picked up and were immediately glad that they had taken the test. 
Long term impact of diagnosis- 3-9 months post diagnosis 
With time (for some a very short period) their feelings altered and became more 
positive.  They were glad that they did the test; this gave peace of mind and they 
would do test again. 
Some considered the positive result a wake-up call which led to increased sexual 
health awareness and safer practices. 
Retest experience 
The re-test experience was valuable to the positive cases- especially the knowledge 
that they were no longer infected.  However they interpreted it as a check to see if the 
original infection had resolved, while the actual aim was to establish if there had been 
re-infection. 
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Testing for further STIs 
Among those who went for the further testing; some expressed anxiety while waiting 
for the results.  Once they had completed this testing, they were delighted this was 
finished and with their negative result. 
Some interviewees did not go for further STI testing (though being advised to) 
because they either did not want it with some considering this health episode finished 
or they did not consider themselves likely to have another STI; while others did not 
have a current partner and thus did not consider further testing relevant. 
Other interviewees planned to have further STI testing when they had time or when 
their partner could go with them.  Some stated a preference to going to their local GP 
for further STI testing- due partially to the convenience of the GP setting and partially 
being familiar with the GP.  
Experience of treatment medication 
One respondent experienced nausea.  The rest had no difficulties- that the medication 
was provided in the doctor’s surgery was appreciated both from a convenience and 
confidentiality perspective.  Attending pharmacies was considered a potential problem 
as one could meet an acquaintance. 
General views on the screening pilot 
The overall opinion of the interviewees regarding the screening pilot was very 
positive.  Interviewees were glad that they participated in screening and they 
considered that the pilot should be continued as the model works well; the process is 
very quick and easy and that chlamydia screening was important. 
Suggestions re improving screening pilot 
The following suggestions were repeated by the interviewees. 
 Provision of increased advertising on chlamydia screening especially for 
males who may not go near a clinical setting routinely. 
 Provision of an alternative to the GUM clinic for the recommended further 
STI testing; “I think pretty definitely is if you didn’t have to go to that STI 
clinic”. 
One suggestion was for STI testing to be based in the FPCs as “that would be 
so much better because you wouldn’t feel as paranoid going in there.  You 
wouldn’t feel kind of embarrassed going in there because you know it’s not 
just for STD testing”.  Others suggested being screened at their local GP 
surgery. 
 Provision of more information on chlamydia to increase awareness of this 
infection. 
 More privacy in the GUM clinic. 
In summary, chlamydia screening, in particular urine testing was very acceptable to 
interviewees.  Interviewees accepted the screening offer for many different reasons 
such as no charge etc.  The use of urine tests removed any potential issue regarding 
interacting with a HCW of the opposite sex.  A positive diagnosis caused an initial 
negative impact which waned with time.  Retesting had a positive impact; however 
the reason for this second test was not understood.  Opinions varied on general 
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practice as a STI testing setting with support for and against this based on the same 
proximity factor.  Though the service was very professional in the GUM clinic 
involved with this pilot, these types of settings can generate negative connotations.  A 
solution suggested by some interviewees is to offer further STI screening outside 
these settings. 
3.6 Post-screening interviews with health care providers 
At the end of the 9-month pilot screening period, 16 providers who had participated in 
the pilot were interviewed.  These included GPs, practice nurses from general 
practices and practice nurses and a GP from the family planning clinic and student 
heath units. 
Qualitative interviews were undertaken as a component of the research to explore 
providers’ experience of the screening model. The purpose of the qualitative 
interviews was to explore the diversity of provider’s experiences of chlamydia 
screening. 
3.6.1 Findings  
Initial reactions to the pilot were overall quite positive.  
Well I thought it was a great idea...  I was all for it and thought it would be great to 
offer it. (Interview 14, rural GP, screened: 2)  
I was interested to do it, I was aware that the incidence was high and that made me 
interested in doing it. (Interview 13, rural GP, screened: 5).  
Opportunistic screening, while deemed valuable and worthwhile also presented 
substantial challenges, many of which were not anticipated by providers at the outset 
of the project. These challenges identified by providers contribute to our 
understanding of lower than anticipated screening rates. To explore the complexity of 
the recruitment process as described by interviewees, we crudely divided it into 
factors which we believe were internal and external to health care providers. These 
factors played a role in who was (or who was not) invited to participate and indeed 
those who choose to accept or reject an invitation to test. These factors are discussed 
below (see Figure 5 for summary?). 
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Figure 5. Summary of recruitment factors 
3.6.2 Factors Internal to the Recruitment Process 
Raising the Subject  
The most usual recruitment approach was for health care providers to ask potential 
participants if they were interested to participate in the screening pilot. 
While some interviewees had no problems, many providers voiced some concern, and 
reported difficulty broaching, the sensitive and potentially stigmatising subject of 
sexual health in a general consultation. In addition, many lay people were starting 
from a very low chlamydia knowledge base. Offering the tests to patients, presented a 
‘risk’ for health care providers because of its possible impact on the lay- professional 
relationship. Some providers felt that the actual process of offering the test created a 
scenario where they had to somehow ascertain if someone was sexually active which 
itself was viewed as intrusive. 
 There are difficulties in general practice… you are not aware 
 If someone is sexually active… and you are not aware if it 
Recruitment factors 
Factors Internal to Providers Factors External to Providers 
Raising the Subject  
Impact on lay-professional relationship 
 
       Resources 
Time is money 
 
Health care provider 
Motivation and experience  
 
Gender 
Male vs female patients 
Patient perception of risk 
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 [chlamydia test] needs to be mentioned…It seemed inappropriate to mention it to 
some people… and some may take offence. (Interview 13, rural GP, screened: 5) 
Some providers felt the actual process of inviting someone to test for chlamydia had 
the effect of not just labelling them as sexually active but also as ‘high’ risk.  
And they might be, just sometimes you would feel are they thinking …that I think… 
they were high risk, because I’m asking them.   (Interview 9, urban GP, screened: 
35) 
How health providers ‘managed’ the potential labelling effect of proposing a test 
varied between providers. One general practitioner reported quite frankly, that she 
stopped asking and essentially withdrew her practice from any further screening.  
 after I while I thought, I’m not going to offer because I felt that in case they felt I was 
you know…, questioning their morality, and I felt that there was an issue… that they 
felt why should I be screened. (Interview 14, rural GP, screened: 2) 
If other health professionals involved felt so strongly, they did not voice it in the 
interview setting. More usually, providers reported that they attempted to minimise 
any particular offence that may have been caused by employing techniques such as 
‘reading’ the patient in advance of the invitation to test. In essence, engaging in what 
might be considered to be selective screening.  
But I suppose it was… you kind of get a feel for somebody first and see if they were… 
you know…willing to talk about it. (Interview 6, practice nurse, urban GP, 
screened: 60) 
Frequently, health providers honed in on the high community prevalence of 
chlamydia and attempted to use this as a strategy to normalise the testing process.  
I would be very particular to say this is just across the board… it’s not because we 
think you have anything… its just, its there, it wont hurt. (Interview 1. practice 
manager, family planning clinic, screened: 78) 
Inviting to test for chlamydia was easier when ‘piggy-backed’ with other, somewhat 
related consultations such as the cervical smear programme, or consultations for 
contraceptive services.  
Sometimes, they were coming in for a different reason… it can be difficult then, to 
change the perspective, like a repeat asthma prescription… that can be trickier… 
often it is easier to bring up if they are in for something like the pill prescription or 
contraception.  (Interview 13, rural GP, screened: 5) 
The timing of the study coincided with the commencement of a national cervical 
screening programme. This perhaps had positive as well as negative effects on the 
chlamydia screening pilot. The recent high profile illness and subsequent death of a 
young female media personality resulted in increased interest in cervical smear testing. 
The timing nearly wasn’t great as regards all the promotional stuff and then the ‘Jade 
Goody thing’.  All everybody was thinking about was cancer and cancer and cancer! 
(Interview 1. practice nurse, family planning clinic, screened: 78) 
Health care provider’s motivation and experience 
It is perhaps not surprising that providers who expressed the most enthusiasm for the 
screening pilot were very often those who conducted larger numbers of chlamydia 
screening tests. Frequently, in many settings a key designated person took the lead in 
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delivering the pilot and guiding colleagues. For those who had lower rates of 
screening, lack of motivation was an issue in at least one setting.  
  P: it was quite hard to motivate people to do the screening.  
 
I: Do you mean the staff or patients?  
 
P: Yes, the staff, to offer the screening because one nurse in particular, she 
just wasn’t comfortable with it, so she didn’t offer it.   
 
I: Ok, and did she say why or do you know?  
 
P: I think that it’s that she was a little bit older and that she didn’t feel 
comfortable to discuss those things.   
 
I: Ok, would she have had any training in sexual health or the STIF course or 
anything like that?  
 
P: No, there was one nurse who got the training as a result of us doing this 
and I think that did help with her interest in you know, encouraging, or 
offering the screen.  
 
Educational preparation and information support were deemed important by a number 
of providers.   
I did the STIF course…which I found really good to be honest… and I have the 
guidelines there on it. (Interview 9. urban GP, screened: 35) 
Information packs and back up support offered by the research health advisor also 
contributed to successful screening by many providers 
P: No, my two favourite bits are probably this  
    [Holds up information leaflet and checklist] 
I: So the checklist 
P: Exactly for ourselves just to remind us, and the information leaflet I think is 
excellent (Interview 15. GP, student health unit 2, screened: 28) 
3.6.3 Factors External to the Recruitment Process 
Time 
Time constraints were raised by most interviewees as the single most significant 
barrier to the recruitment process. Many providers stated they simply did not have the 
time to offer the test to every patient attending in the target group. Several were 
concerned at the extra time it added on to consultations and felt in particular it was 
time consuming in the initial consultation. Only three providers were not concerned 
with the extra time it added on.  
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It took about an extra 3-5 minutes and when you are busy that can delay your other 
appointments…. had time and if they were in the age bracket, I would ask those I 
thought might be sexually active. (Interview 3. rural GP, screened: 18)   
A number of providers felt even though initial offering of the screening only took a 
few minutes, concerns about the accumulative impact on workload were still very 
relevant if screening was to be offered opportunistically to every patient.  
Suppose it boils down to trying to make that, I mean, I suppose, it was, I mean, you 
know, three to four minutes or five minutes in some cases doesn’t sound like a lot, but 
if you are doing it for every fifteen minute consultation, it is a lot.  (Interview 9. 
urban GP, screened: 35)  
Two providers in one student health settings were too busy to offer the screening 
because of time pressures, one of whom stopped the process due to time pressures 
The time…Is too difficult on top of our particular practice which is very busy.  That’s 
what we found.  , so wouldn’t be asking everyone do they want it. (Interview 10. 
student health unit 2, practice nurse, screened: 28) 
The impact of positive results was considered a bigger concern for many  
I think it’s where you get positives that you know things get a little bit more time 
consuming (Interview 3. urban GP, screened:18) 
Gender  
The gender context is also an important recruitment issue. Many interviewees 
reported that there were recruitment differences between men and women. Firstly 
some providers found that they asked more females than males.  
Explanation for these differences is multifaceted. Some of the issues raised include, 
less easy access to a male target population in the clinical settings.  Many also said it 
was difficult to offer it opportunistically to men because this group rarely attend 
general practice ‘unless they are worried about something’ (unlike women, who more 
usually attend general practice for contraception and related services). Several 
providers pointed out that male attendance in the study target age group was generally 
low. Providers in both student health units remarked if males were attending they are 
generally quite sick and therefore inappropriate to offer the screen.  Also for this 
reason, in a male consultation other issues came to the fore and a screening test for 
sexual health was simply not remembered.  
 it probably wouldn’t have crossed my mind, because very often if you get males in at 
that age, they might have been coming in to have sutures removed or something 
where you are not actually on that train of thought, so it might not have even entered 
my head to offer. (Interview 7. rural GP, practice nurse, screened:15) 
Secondly, when men were asked, providers reported higher refusal rates with men, 
compared to their female counterparts and this was particularly commented on in 
student health settings. One participant estimated two thirds of men refusing the test 
offer, describing it as a ‘closed door’.  
I.  any thoughts on why you think… they refused?  
P: Well a few could not give a sample at the time.  That was their excuse that they 
gave me….. …. they said, oh I can’t actually give you a sample now, I’ve just been. 
But why they don’t want it, I don’t know is it just fear of it or not wanting to know 
about it, not wanting to deal with it.  Or maybe a lack of understanding.  But a lot of 
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the males that I asked in terms of the ones that refused, a lot of them were male.  I 
would say, out of that ten percent, probably I would say maybe seven out of the ten 
percent. (Interview 2. urban GP, screened: 64)  
Many providers found males more defensive and dismissive than their female 
counterparts, with some ‘just laughing it off’. 
But of the guys, there was sort of a, they were quite dismissive of it and just didn’t 
have any interest in taking part… which is kind of concerning.  (Interview 2. urban 
GP, screened: 64) 
Providers felt it was a ‘denial thing’ in males and a ‘lack of understanding’ of the 
asymptomatic nature of chlamydia with men tending not to worry about the long term 
consequences.  Lack of knowledge among men and their perceptions that chlamydia is 
more associated with women is highlighted in a participant’s comment;   
 Men don’t get chlamydia of course. (Interview 5. practice nurse, family planning 
clinic, screened: 78) 
The gender of the health care provider was also pertinent. Many female providers felt 
uncomfortable raising the issue with men and attempts were made to encourage male 
GPs within the practices to offer it to male patients.  
On the other hand, uptake in females was quite high with little refusing the test and 
also providers reported being more comfortable offering the test to females in related 
consultations.   
Also several providers perceived the long term benefits of screening more relevant to 
females.  
… you tend to maybe go more for the females, I suppose, just because thinking of the 
consequences, females and younger ones,. (Interview 12, rural GP, screened:10) 
with the girls, they are delighted.  obviously it’s a positive thing for them like if you 
have a chlamydia test, if you have it you can treat it, it might help around 
infertility……….. Whereas with the fellas, if you have chlamydia we can treat it to 
stop you giving it to somebody else.  So its, its easier to kind of, I felt, sell it as a good 
thing for the girls I suppose. (Interview 12 rural GP, screened:10) 
Patient perception of risk 
Providers reported that that chlamydia screening did not have much relevance to the 
lives of some patients. Providers reported that many patients considered that they 
were not personally ‘at risk’ and on that basis excluded themselves from screening 
pilots.  
 But I think that the most common reason for people refusing is that they don’t think 
they are at risk, that they haven’t had multiple partners or they are not aware of their 
partner you know, having, or where they have used barrier contraception all along.   
(Interview 3. urban GP, screened:18)  
A discrepancy between what lay and professional deemed to be ‘risky’ was evident in 
the narratives.  
  I would usually say if you have ever had unprotected sex, and I think you nearly 
need to go into it further as what unprotected sex is, because you know, they think 
they use condoms all the time but when you go in to ask further questions they 
actually don’t.  You know, so I think they don’t see themselves at risk. (Interview 16. 
practice nurse, student health unit 1, 81) 
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Many providers referred to the knowledge deficit which they believe existed about 
chlamydia and it’s symptoms in their patient population.  
And I think there is still very little knowledge around about chlamydia and the lack of 
symptoms with it, and I suppose it would make it more feasible in general practice if 
they didn’t all look so surprised and you know, blank when you  mention something 
like chlamydia. (Interview 9. urban GP, 35) 
Specimens  
Providers indicated high levels of acceptance with the sampling method (specimens) 
used. Urine samples were offered to all males and urine samples or cervical swab 
were offered to females. Providers were vociferous in the advantage of urine samples, 
with ease of method for patients and the implication also for human resources and 
time within the practices.  
Urine testing were ‘easy to do’ and ‘easier to offer’ because they were less invasive 
for patients; 
Yes, and I found that was, it was much easier to offer.  Especially when somebody 
was in for something unrelated to be able to offer urine than to have to do an invasive 
test.  (Interview 9. urban GP, screened: 35) 
While cervical swabs testing for chlamydia were also deemed useful and convenient 
when taking a smear. 
The swabs would have been mainly if I was doing a smear on a female patient at the 
time, it was as easy to do a swab as to send them off to the toilet which takes a while.  
(Interview 9. urban GP, screened: 35) 
Providers re-iterated the impact of invasive testing on patients especially for male 
patients  
That hugely increased the acceptability, people were willing to consider it, that you 
know, because last week, we had a gentleman in who wanted it, and but he said to us, 
there was no way, he couldn’t stomach the idea of having the swab, he did the urine 
test, , so, the fact that the urine test was available would just so much more increase 
the rates of people who would be using it and availing of it.  Yes. (Interview 8. 
urban GP, screened: 60) 
The availability of the urine testing as a method of sampling was welcomed as urine 
testing for chlamydia was previously unavailable in the region.  
.., that’s the attraction of doing the urine test, I suppose in other places I have worked, 
urine testing was available for everybody.  So I suppose that’s a bit unfortunate in X 
that they are none. (Interview 11.urban GP, screened:18)  
Logistically, urine tests were seen to be quicker to do for providers have an 
examination room was not required and a consultation may not have been required. 
The recommended interval of two hours since last urination was not seen as 
problematic for most providers with only two providers commented on it.    
I suppose the peeing in the last two hours, I don’t know what it is about people who 
come into the doctor, they always seem to pee before they come, you know?  And 
doctors are notoriously looking for urine samples, so that probably would have been 
the worst one. (Interview 10. student health unit 2, practice nurse, screened:28) 
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Other logistical issues were also raised in relation to taking and organising samples. A 
minority of providers reported that submitting specimens to the laboratory within a 24 
hour time frame could be difficult.  Laboratory restrictions on receiving samples by 
five pm each evening meant some practices had to limit screening to mornings if 
delivery only occurred once a day. 
When we weren’t able to get samples over in the afternoon and we probably missed a 
lot of patients based on that.  And we didn’t want the patients having access, they 
weren’t allowed to be bringing the samples over so it had to be a member of staff 
from here and the girl on the front desk couldn’t drop everything and go over, so that 
was a bit inconvenient like, four o clock as a dead line wasn’t great… (Interview 
2.urban GP, screened: 64)  
Organisation/administrative issues 
The overall administration burden generated by the study was referred to by a number 
of providers. ‘Too much paper work’ was a common complaint as well as delays in 
receiving patient results.   
Probably the length of time it probably took to get back some of the results.  Because 
we were kind of telling them they would get them back in three or four weeks and 
sometimes it went a little bit longer… (Interview 5. family planning clinic, 
practice nurse, screened: 78) 
Due to anonymous screening providers were unable to receive results electronically 
and this caused problems for filing and identifying patients’ results. Documents for 
the screening pilot had to be filed separately in order to identify code and patient 
details.  
One key provider in the practice, usually a GP or a practice nurse generally took 
responsibility for the organisation and distribution of results which for many helped 
ensure the system worked efficiently.  
Giving patient results  
Providers reported in the main that the process of giving patient results was 
uneventful.  Providers’ current processes and systems were used where possible to 
minimise disruption.  Providers were given options on how they might like to receive 
their results
4
.  In most cases in the screening study patients were informed of their 
negative results over the phone. A number of providers stated that they preferred to 
give a positive chlamydia result face to face, although this was not always practical. 
Providers also reported that when they were giving out positive chlamydia results, 
they had to try and manage a multitude of patient reactions, including: shock, surprise 
and upset.  
Partner Notification   
Partner notification is the process where people who have exposed to a STI are 
notified of the exposure and invited to attend clinical services. In the current 
Chlamydia screening programme and following British Association for Sexual Health 
guidelines [7] it was recommended that all partners within the previous six months 
                                                 
 
4
 See Appendix 3 for Screening form used in pilot study 
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were traced and invited to attend for testing and epidemiological treatment. In the 
research study, a community based research health advisor was available to conduct 
partner notification by phone. Providers who had experience in sexual health choose 
to carry out partner notification themselves while the majority of providers referring 
to the research health advisor. Providers were advised to distribute the contact cards to 
patients to assist in tracking the process. The purpose of these cards is to inform 
contacts that ‘may have been exposed to Chlamydia’  
A real issue  
A number of health care providers identified partner notification as a key concern of 
patients who are diagnosed with Chlamydia infection.  
Other than the shock of having it…that’s [partner notification] a real issue for 
lots of people. (Interview 15. student health unit 2. GP, 28)  
There was an almost universal acceptance of the importance of notifying partners 
there were also real world issues that also were raised. 
So they all understood that a partner should be traced and contacted…and in 
their own heads… they wanted to try and figure where this came from … or 
where they got it… (Interview 8. urban GP, 60) 
A difficult issue to discuss 
While the benefits of partner notification were raised by some, the difficulties 
discussing the process were raised by an even larger number of participants. An initial 
shock factor makes partner notification discussions difficult in the early stages  
I think they find it hard… it takes, it's like any bad news, you know, it hits you 
with a wallop in the beginning… and then you mull over it… and then you 
suck it up... and get on with it, do what has to be done.   (Interview 15. student 
health unit 2. GP, 28)  
Health care providers engaged in a complex process of managing an array of emotions 
and issues which the partner notification process brought up 
Either it was… as with the first person… it was a very bad break up… and 
then with everyone else… I think it was an anger kind of thing first… if they 
were in a long term relationship…  And they just wanted to get it out there 
themselves with the partner… before they discuss anything with 
me…(Interview 6. urban GP, practice nurse, 60) 
Nonetheless the complexity of a diagnosis of chlamydia in a presumed monogamous 
relationship raised issues such as infidelity, which is often reflective in any sexual 
health work. 
The blame game, because that’s where the biggest problems for people are 
actually about it, it’s the whole relationship, psychological thing, and you 
know, the blame thing about.  Oh well, you know, I have only been with one 
person, who were you with and you know, I have never been with anyone else, 
you must have cheated on me and all this kind of stuff.   
…This comes up in any sexual health, any STI issue (Interview 10, student 
health unit 2.practice nurse 28) 
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Time 
The time consuming nature of partner notification work was described by many 
participants. 
I think it would be… it does… counselling about contact tracing and getting 
partners back… that would certainly be…it would be time consuming… 
(Interview 1, practice nurse, family planning clinic screened 78) 
The potential workload of partner notification was seen as not being ‘financially 
viable’ for one practice. 
I honestly think the only barrier, and I can, the only barrier that I felt was just 
I didn’t have time to go down the road of, I know we only had the one positive, 
but had we had more.  I would have felt that whole workload would have been 
too much to take on and I think by taking up all the time, I don’t think the 
practice would have been happy.  All that time was being taken up with 
something that wasn’t actually being financially viable to the practice if you 
see what I mean? (Interview 7, practice nurse, rural GP screened:15) 
While a number said that they managed to conduct the process as they did not have 
large numbers coming through, it would have been a different scenario if they had 
larger numbers of patients diagnosed with Chlamydia infection. 
But, I suppose while it was only a small pilot project at the time and we didn’t 
have a massive amount, but if it was a full time thing it would be, like, we 
wouldn’t be able to take on that kind of work really.  It would be much easier 
if there was somebody else to, they had no problem taking in the samples and 
doing all of that, but then, you know, letting somebody else take over the 
positive side of it would take a lot of work away. (Interview 5, practice nurse, 
family planning clinic, 78) 
Many participants used language to suggest that partner notification was something of 
a chore and they were more than happy for an external person to carry out the process.  
Most of them were going to talk to you anyway so that got us off the hook a bit 
(Interview 1, practice nurse family planning clinic screened: 78) 
The referral process  
Participants reported discussing partner notification with patients with ‘most of them 
happy enough to do it themselves’.  
The doctor went through that with them… and then it was left up to the 
patient to do it…. She went though it with them and then left it up to 
themselves to do it… (Interview 6. urban GP, practice nurse, 60) 
Contact cards were uniquely devised for the study and were modelled on contact slips 
used in GUM clinics throughout the UK and Ireland. One provider who conducted 
extensive partner notification in the practice felt the cards were useful and were used 
by patients.  
P: Well I think it’s great to have the number on them, the code like for you to 
link up in the clinic in case they didn’t come here, so you know… 
…and you know, it explains on the front as well, you have been exposed, so I 
suppose they would phone their partner and they take a card just in case you 
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weren’t too sure where you were going to go and the clinic details were on the 
back for the walk in 
I: Right, would you feel many would have handed them over to their partners 
or not?  
P: Yes, yes, I feel they did.  
I: They did yes.  
P: Yes.  I guess they were a reminder in the pocket if nothing else.   
 (Interview 16, student health unit 1. practice nurse, 60) 
Nobody reported receiving any cards back to their service and in instead received 
verbal reports from contact attending the service.  
Nobody came in holding the card that I recall, people would have come in 
saying I’ve been told I’ve been in contact with Chlamydia… 
(Interview 15. student health unit 2.GP, 28) 
Role of the research health advisor  
Providers were happy to refer partner notification to the health advisor with many 
participants reported that ‘she was easily available at the end of the phone’. 
Communication between the services and the heath advisor was seen to be key. 
Several providers expressed concerns about the feasibility of partner notification in 
primary care within their current systems. The ‘labour intensive’ and complex nature 
of partner notification called for additional resources to ensure feasibility in these 
settings. Although some providers expressed preference to refer to GUM clinics, most 
were willing to take it on with the necessary supports in place.  
Provider overall perspectives on feasibility 
Despite significant barriers to offering screening most providers when asked about 
feasibility favoured a chlamydia screening programme in primary care. Primary care 
was perceived to be ‘an ideal place and ideal time’ to offer opportunistic screening  
In contrast, one participant explained her reservations about the appropriateness of 
raising the subject with patients in general practice which she felt was a barrier to 
feasibility; 
I wouldn’t be overly confident that it is generally.  I think you would need a lot of 
supports in place   And I would have, with the best will in the world hoping to get 
much higher numbers than I did, and I didn’t…can be awkward because they are 
coming in for something completely different  (Interview 9, GP urban, screened: 
35)  
Feasibility in primary care was dependant on a number of factors. Funding for 
providers and the availability of urine testing was seen as essential to any future 
programming. Adequate financial remuneration
5
 was a key issue and the need for 
funding was emphasised by the majority of providers. The meaning of ‘adequate’ 
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 In the context of the screening study, provider’s participation was optionally and largely 
unremunerated. Provider received €25 for positive case detected 
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varied between providers. For a minority, a consultation fee to cover the cost of 
dealing with a positive diagnosis was sufficient and providers were ‘just happy to be 
able to offer the service’.  Two such people were practice nurses and perhaps may not 
have been directly involved in budgetary management for the service. One participant 
felt that lack of funding should not be a barrier to a screening programme. 
While two providers felt the initial offering would require minimal remuneration 
(twenty-thirty euro), a larger number of providers felt it ‘would have to be cost 
effective for GP’s to continue doing it. A normal consultation fee was considered 
appropriate. 
There were varied opinions on the feasibility of chlamydia screening in student 
settings. While providers acknowledged the appropriateness of offering screening in 
this setting, time pressures was seen as a major barrier for one student setting. 
It was also highlighted in this setting the practice nurse is in a unique position to offer 
the screen as most students are triaged by the nurse. 
I think here we have the benefit you know, that most of the students come through the 
nurse, I think that’s a huge thing to be honest because you know, the nurse, the idea 
of the students seeing the nurse here would be that it cuts down on the doctors time.  
(Interview 16, practice nurse, student health unit 1, screened: 81) 
Many providers were overwhelming in favour of the benefits and the need for 
screening in this target group, chlamydia was seen as ‘an important disease to screen 
for’. Prioritising chlamydia screening particularly in the current economic climate was 
difficult, with providers comparing the long term benefits of screening interventions 
with interventions such as the HPV vaccination. The majority of providers felt 
screening should be considered moderately to high as a priority by funding agencies. 
The long term human and economic costs associated with infertility and pelvic 
inflammatory disease were considered to be very significant by providers. 
Provider’s recommendations for screening in primary care 
A number of strategies and recommendations to help improve feasibility were 
identified by providers.  
Three providers when asked about future recruitment in general practice suggested 
systems where patients ‘could drop in a sample without seeing a health professional’.  
… Or a simpler system where you could just leave a sample without seeing the doctor 
or filling out questionnaires. Not all have to go anonymously… it is not an issue for 
most people… checking and double checking is laborious… just simply having the 
testing available for a longer period… people will get used to the idea.  (Interview 
13, GP rural, screened: 5) 
Having the service available at all time and ‘patients requesting a screen themselves’ 
was seen appropriate by some. 
In order to address the time issue, some providers suggested more nurse-led screening 
which could relieve the more expensive GP time. 
Write and invite  
 A call recall system was also raised in three providers.  
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Like happens in the immunisation programmes or even the cervical smear 
programme… Yes, something like that would be more beneficial (Interview 13, 
GP rural, screened 5) 
Media 
Half of providers felt that the use of the media was also an important aspect in a 
screening programme. Parallel were drawn with the new national smear campaign, 
Cervical Check, ‘a heavily advertised campaign’ would help to increase patient 
uptake as well as assisting providers offering the test in a general consultation. 
Patients were more likely to accept if they felt everyone was being asked across the 
board. A campaign could also be a useful strategy in minimizing any adverse effects 
of labelling patients when offered a test.  
Otherwise I think if there was a media campaign attached to it, it may be much easier 
to do. ….. there is still very little knowledge around about chlamydia and the lack of 
symptoms with it, and I suppose it would make it more feasible in general practice if 
they didn’t all look so surprised and you know, blank when you  mention something 
like chlamydia.  (Interview 9, GP urban, screened: 35) 
Targeting males 
While acknowledging difficulties on how best to target men, two providers suggested 
using the media to target men.    
if they think they can go in and get a urine test done, I can’t see why men wouldn’t go 
for it an awful lot more… It would be more of an advertisement thing though of 
course, and the posters would have to show just as many boys as girls like really.  Or 
boy’s only posters….   (Interview 5, practice nurse, family planning clinic, 
screened: 78) 
3.7 Interviews with the laboratory team 
Increased workload using urine samples: significantly more work was involved in 
processing urine samples (in comparison to swabs which are routinely processed in 
the study laboratory).  The design and costs of the testing process meant that it was 
necessary to accumulate a sufficient number of specimens to form a batch for testing, 
particularly in the early stage of the pilot when recruitment was slow.  These 
specimens had then to be frozen for batch testing.  Defrosting these led to increased 
working time.  This impacted significantly on mean turnaround time. 
This issue is unlikely to be problematic in the context of a laboratory which is 
processing urines routinely and is resourced to contribute to an ongoing national 
screening programme.  
Non-clinical PIP screening: large numbers of samples were submitted. This combined 
with other circumstances created pressure on the laboratory performing the testing. 
This issue would is unlikely to be problematic in the context of a laboratory resourced 
to contribute to an ongoing national screening programme.  
Mislabelling was a problem with some samples. More samples from the non clinical 
PIP settings had insufficient and/or incorrect details. Resolving these had time 
implications. Up to 20% of the total sample number would have been discarded if 
rejection criteria had been followed without efforts to clarify.  Sending out results was 
not a problem for laboratory staff.  
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4. Discussion  
The opportunistic Chlamydia Screening in Ireland Pilot Study that was conducted in 
the Galway region in 2008-09 built on a body of evidence, which included: 
 Qualitative and quantitative interviews on the acceptability of screening, from 
the perspective of Irish 18-29 year olds in urban and rural settings, and 
students in two Higher Education Institutions (HEIs) – see Background 
Studies:  Acceptability and Feasibility of Screening;  
 Qualitative interviews on the views of providers (doctors and nurses in general 
practice and student health units around the feasibility and design of screening 
programmes - see Background Studies:  Acceptability and Feasibility of 
Screening; 
 Lessons learned and materials from an earlier study in HEIs conducted by 
some of the Galway based-researchers [2] and  
 Advice from colleagues of the English National Chlamydia Screening 
Programme (NCSP), Health Protection Agency, London; and 
 Adaptation of materials from the NCSP and the British Association for Sexual 
Health and HIV (BASHH). 
4.1 Study implementation 
The results of the background studies, lessons learned from other settings and the 
participatory approach used by the Research Health Adviser (RHA) meant that the 
study packs and materials supplied to participating sites (information sheets, forms, 
questionnaires, and management algorithms) were fit for purpose, both for study 
implementation and monitoring
6
    
The lower than anticipated numbers of young people at the initial nine participating 
general practices necessitated the recruitment of a further 22 practices.  A feature of 
the implementation, as is commonly found in research pilot studies, was that close 
support and monitoring as undertaken by the RHA solved early teething problems at 
participating practices.  
The intensity of support reduced over time, as participating practices became more 
familiar with the protocols.  However, the first lesson from the study is the importance 
of there being a designated trained individual who has overall responsibility for 
driving and monitoring the implementation of chlamdyia screening and community 
interventions (including partner notification, retesting and other STI screening), which 
require different components of the health services to work in a coordinated way. 
The post-pilot provider narratives reflected the diversity of participant’s experiences 
and are rich with enthusiasm and interest in exploring the potential of chlamydia 
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screening in Ireland. The challenges, however, that are inherent in offering such a 
programme resonant strongly throughout the dialogue. 
Offer rates  
The low offer rates in general practice and in SHUs (less than 0.5 to 9% of those 
eligible) reflect the time pressures on providers in primary care.  Time constraints in 
busy clinical practices were identified by the providers as a major barrier to effective 
chlamydia screening and are likely to represent what happens in ‘real life’.  There was 
a not unexpected but stark difference between the expectations of much higher rates 
and the realities in practice.  This reality of low coverage is of crucial importance in 
considering the potential for population health outcomes in terms of reduced 
transmission and prevalence of Chlamydia trachomatis and prevention of PID (see 
Economic Evaluation Report).  In common with our pilot, an Australian randomised 
controlled trial (RCTs) found that the most common barriers to increased chlamydia 
testing included: lack of time (29/43, 69%) and difficulty remembering to suggest 
testing to patients (9/43, 21.4%) [10].  The latter finding was also found in our pilot 
leading to an intervention of computer stickers being used to act as reminders. 
The administrative tasks related to our Chlamydia screening pilot were raised by a 
number of providers. Some of these tasks were related to the research nature of the 
pilot. 
It is likely that financial incentives would have increased offer rates- in our pilot 
providers only received a payment if they treated a positive case (€25, $AUD33).  The 
need for adequate financial remuneration was a key theme in the provider interviews.  
In the UK, as part of their chlamydia testing pilot, financial incentives of up to £25 
pounds (approximately $AUD50) were offered to practices for the opportunistic 
chlamydia testing of young women aged 16 to 24 years. General practices had an 
effective screening rate (ESR) of 46% in the target female population in one of the 
health authorities [11].  
In contrast, with the introduction of the English National Chlamydia Screening 
Programme (NCSP) in 2003, when financial incentives were discontinued, the ESR 
initially dropped significantly in general practice to around 10% [12].  However 
recent NCSP uptake rates (2009/2010) have increased significantly with the 
proportions tested in 2009/10 were approximately 47% and 25% of sexually active 
young women and men respectively [13]. 
In Australia, the aforementioned RCT examined whether offering general 
practitioners (GP) a small incentive payment per test would increase chlamydia 
testing in women aged 16 to 24 years, attending general practice [10].  General 
practice clinics (n = 12) across Victoria, Australia, were cluster randomized to receive 
either a $AUD5 payment per chlamydia test or no payment for testing 16 to 24 year 
old women for chlamydia.  They found that this small financial incentive alone did 
not increase chlamydia testing among young women attending general practice.  
However, two general practitioners dropped out of the non-payment group.  The 
authors considered it possible that small incentive payments in conjunction with 
reminder and feedback systems may be effective, as may higher financial incentive 
payments.  Our findings indicate more support for the latter suggestion of higher 
remunerations being necessary. 
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The interviews with providers indicated that the decision to offer testing was selective 
rather than random.  Tests were more likely to be offered when there was time to give 
to it (when providers were under less pressure) and when it was considered ‘context 
appropriate’. Offering screening to males was more difficult than to females.  Refusal 
rates were reported to be low (it was not possible to get providers to quantitatively 
record refusal numbers), which reflects the acceptability of screening.  The lower 
number of screened men, especially in GP settings, may have partly reflected doctors’ 
and nurses’ perceived reluctance to offer screening to males.  Most providers’ 
perceived male patients would not want an offer of a STI screening during a non 
sexual health consultation. There may also be a reluctance of men to accept screening. 
Males in the target age group were reported to have lower attendance rates however; 
screening was further hampered by lack of knowledge and fear around invasive 
testing methods in this group.  The use of peer-led screening strategies such as ‘pee in 
the pot’ days may prove useful to help tackle the challenge of how best to reach men 
in this age group for screening. Professional views of patient perception of risk as a 
barrier to screening recruitment were discussed.   
Staff motivation and experience was also an issue during recruitment. Professionals 
with a background in sexual health appeared better equipped at managing the 
potential labelling effect and overcoming difficulties in raising the subject in a general 
consultation.  
Screening in clinical and non–clinical settings 
In contrast to screening in the clinical settings, where it took nine months to conduct 
460 tests across 23 practice settings; the ‘pee-in-a-pot’ (PIP) events in two non-
clinical HEI settings generated 538 samples in 6.5 days in total.  Non-clinical PIP 
screening also yielded 77% (191) of all male specimens in the study.  Promoting 
chlamydia screening to young people in non-clinical settings, where they could 
discretely and anonymously take a test, was acceptable among male and female 
students. 
The mean number of specimens per practice was higher in urban, group and training 
practices which is probably a reflection, at least in part, of practice size and patient 
turnover. In a small number of practices (four), there was highly motivated clinical 
staff who ‘championed’ screening with screened numbers greater than twenty.  
However these sites still had low offer rates. 
In general practices, there were more GP screeners (n=19) than practice nurses (n=7) 
in the pilot.  In this type of setting, doctors took the majority of specimens while in 
FPC and SHUs the majority of specimens were taken by practice nurses. This reflects 
the nurse-led processes of these sites. 
Specimens 
Regarding sampling, there was wide acceptance of the non-invasive nature of urine 
testing with participants and providers expressing support for this method. 
The time to take the test varied widely, though with a fairly consistent average time 
across the three clinical settings: median 5 minutes, range 2-20 minutes.  This reflects 
different clinical consultation styles.   
Twenty nine (29.9%) of the cervical swabs processed were taken from participants 
who were outside the recommended age interval for cervical smears (25- 60 years).  
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The majority of these were done in general practice.  Reasons for having a cervical 
swab taken may include a request by participants for a cervical smear test or a full STI 
check-up.  While we don’t know whether cervical smears were taken in conjunction 
with these cervical swabs, there may be a training need if cervical smears were taken 
inappropriately. 
Time to results 
The time taken to receive results varied in the pilot study with delays experienced by 
some participants. From interviews with participants this delay in receiving test 
results caused some anxiety and uncertainty.  The delay related to issues specific to 
the operation of a pilot study that would not apply in a routine service context.  
Urine samples were the main specimen type requested during the pilot study, with 
providers encouraged to take endocervical swabs from women, only where this fitted 
with the reason for the women’s visit (e.g. for a cervical smear test). However, the 
routine tests for chlamydia in the laboratory used in the pilot study are vaginal, 
cervical and urethral swabs. Routine clinical specimens are reported within a week of 
submission in almost all cases. Efficient processing of urine samples within the 
financial constraints of the study meant that it was necessary to accumulate a 
sufficient number of urine specimens to form a large enough batch for testing.  
The issues in relation to the turnaround time and specimen type for this project are 
entirely related to the practical difficulties of accommodating the extra work of a 
once–off research project at the lowest practical cost within a laboratory that was not 
specifically set up for the purpose and which did not have  any spare capacity.  
This would not be an issue in the context of an ongoing screening programme with a 
structured and resourced laboratory service component. In a high throughput national 
screening programme, economies of scale would allow most specimens to be tested 
within 2-3 days, which would be more appropriate in terms of clinical management.  
4.2 Results of Screening  
Sexual Activity Risk factors among screened study population 
Risk factor data were only obtained from those screened in clinical settings. Males 
were significantly more likely than females to have had high numbers of sex partners, 
a new partner in the last 3 months and more that two partners in the last year.  This 
suggests that while fewer men were screened (12.4% of those screened in clinical 
settings), those at high risk were screened.   
Comparison with the responses to these risk factor questions in the pre-screening 
survey in primary care settings (see Background Studies: Acceptability and 
Feasibility of Screening) shows that males had a very similar profile: 56.8% (pilot 
study) versus 55.4% (primary care survey) reporting two or more partners in the 
previous year. However, the proportion of screened females who reported this risk 
factor (35.6%) within the screening pilot was somewhat higher than the 25.2% of 
females in the pre-screening survey. This suggests a slightly higher risk profile for the 
screened females. 
Both sets of clinical setting attendees (male and female primary care survey 
respondents and screened participants) – were more likely to have 2 or more partner 
in the previous year (31.9% and 38.4% respectively as a combined sex rate) than the 
same targeted age group within the Irish Study of Sexual Health and Relationships 
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(ISSHR) [14] (21.2%) [personal communication with R. Conroy, RCSI].  This 
suggests that those recruited in clinical settings, whether for a survey of STIs or for a 
chlamydia screening test, represent a population at somewhat higher risk for STIs than 
the general population.   
This may be because of some degree of pre-selection by health service staff, who may 
have preferentially selected those they consider more at risk of a STI based on sexual 
history.  It could also be because those who considered themselves more at risk, 
because of multiple or recent changes of partners, were more likely to accept a 
screening offer.  Other factors could include changing sexual behaviour patterns, 
compared to approximately six years ago when the ISSHR data were collected.   
Positivity rates  
This is the first published screening pilot to include primary care settings in Ireland. 
The overall rate of 4.8% CT positive cases (95% CI 3.5-6.1), 4.8% in females and 
5.2% in males, is consistent with, positivity rates in similar screening studies 
internationally and within Ireland.  The positivity rate in the non-clinical PIP setting 
was lower (3.9%) than in clinical settings (5.9%).   
In the English NSCP, overall positivity rates have averaged 7.6% in men and 9.3% in 
women, based on a total of 370,012 screening tests reported [15].  A systematic 
review estimated UK prevalence rates of 4-5% for general population women under 
20 years and 8-17% in women under 20 attending sexual health services [16].  The 
authors of the review assumed, in the absence of data, that males had similar rates. 
The males attending clinical settings had a statistically significantly higher positivity 
rate (15.8%), compared to males in non-clinical settings (2.1%). One plausible reason 
for this finding is that a high proportion of the men screened in the clinical settings 
recognised themselves to be at risk of an STI with self-selection by service attendees 
is likely to be plausible. Also, selective screening by providers of males at higher risk 
may have contributed.  
However, these numbers of male positive cases were small (9 from 57 cases in 
clinical settings, compared to 4 from 191 in non-clinical settings).  As the study was 
not designed as a prevalence study, these chlamydia positivity rates cannot be 
extrapolated and generalised to any specific population of young men and women in 
Ireland.  What we present are the positivity rates in those who accepted the offer of 
screening. 
With the overall positivity of 4.8%, the positive predictive value of the Roche Cobas 
Taqman CT test, v2.0 used in our study is 96%.  This is based on a sensitivity of 
95.7% and a specificity of 99.8% for urine testing of both sexes: as is reported in the 
Roche Cobas Taqman CT test, v2.0 Preparation kit.  
Risk factor associations 
Of the two risk factors routinely used as risk indicators, (‘2 or more partners in the last 
12 months’ and ‘new sex partner in the last 3 months’) only the former was a 
potentially useful discriminator between those who tested positive and negative in 
clinical settings, with a crude odds ratio (OR) of 2.4 (0.9 to 6.6) which is not 
statistically significant. The English National Chlamydia Screening Programme has 
reported significant associations with both risk factors in both women and men [15]. 
Our findings may reflect the lower screening numbers.  
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Much of the recent literature reviews and randomised controlled trials (RCTs) focus 
on the importance of high risk groups and the need to target screening and case 
finding strategies [17;18]. However, there are two important findings which merit 
further research and discussion on using a risk factor pre-screening approach in 
Ireland;  
1. many positive cases would be missed: 23,421 (37% of positive cases) in the 
English NCSP and 9 of 21 (43%) of positive cases in the Chlamydia Screening 
in Ireland Pilot Study answered ‘no’ to the questions ‘two or more partners in 
the previous year’; and 26,206 (41% of) cases in the UK programme and 13 of 
21 (57% of) positive cases in this Irish study reported no to ‘new sex partner in 
the past 3 months’ [15]. 
2. Low acceptability:  the very clear message from young people in the 
qualitative studies (see Background Studies: Acceptability and Feasibility of 
Screening) was that directly questioning them on their sexual behaviour would 
deter them from accepting offers of screening. 
Only 8% of test positives reported pain passing urine and 4% reported a discharge, 
suggesting that there is little utility in using symptoms as a predictive indicator of 
infection.  However again these findings are based on low screening numbers and do 
not reflect the findings of two Irish prevalence studies [2;19].  In one study 9% of the 
positive cases had suggestive symptoms at the time of the screening, these were not 
presenting with these, indicating a low level of understanding of potential STI 
symptoms [2].  While, it is likely that these symptoms were mild and not impacting 
on the individuals’ daily activities this was still worrying as having suggestive 
symptoms significantly increased the risk of a positive test.  
4.3 Management of cases 
4.3.1 Treatment 
Almost all positive cases received their treatment in primary care settings, suggesting 
that treatment of chlamydia in primary care is acceptable and feasible for both 
providers and participants. The treatment protocols and standard operating procedures 
used during the pilot worked well for providers.  
4.3.2 Retesting 
Two thirds (66.6 %) of those screened in clinical settings returned for a retest to these 
settings.  This compares well the Netherlands Chlamydia screening programme where 
68% of those who were positive did participate when they automatically received a re-
screening invitation 6 months later [20].  However none of the PIP participants 
returned for retests to the GUM clinic. Urine testing was not available in the student 
health units at the time, thus retesting at the GUM clinic (which involved an invasive 
test) may have deterred participants for attending. 
All those tested had negative results.  This is surprising based on recent findings from 
studies in other countries such as the Netherlands which has reported, a high re-
infection rate of 8.2% [20]. However in this Irish pilot only 50% of positive cases 
were retested.   
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4.3.3 STI Screening 
Just under half of the positive cases (n=25, 52.1%) had further screening for STIs, all 
known results were negative. Most providers reported not having the resources to 
offer comprehensive STI services and preferred to refer participants to the GUM 
clinic.  However, providers expressed interest in availing of further training in 
management of STIs and partner notification. Provider interviews showed varied 
approaches and practices in the management of STIs in primary care, suggesting the 
need for standardized practices, supports and guidelines.  The full range of laboratory 
tests for STIs is not uniformly available in Ireland- these should be standardised. 
4.3.4 Partner notification 
The majority of providers had concerns about partner notification in primary care and 
viewed this as labour intensive and not feasible. During the pilot most were happy to 
refer CT positive cases for partner notification and follow-ups to the RHA, and 
providers reported in post pilot interviews that this approach had worked well.  
Based on this pilot study, it would appear that partner notification is not feasible in 
primary care settings in Ireland, except through the provision of additional resources, 
such as a community based health adviser. 
In 2001/2002 a randomised controlled trial in England compared the effectiveness of, 
and resources used by, two strategies for managing cases of chlamydia diagnosed in 
primary care: (i) partner notification by trained practice nurses at the time of 
diagnosis, with telephone follow up by health advisers; and (ii) referral to a specialist 
health adviser at a genitourinary medicine clinic [21].  The trial was part of the 
chlamydia screening studies project (ClaSS), a population based study in which men 
and women, selected at random from the lists of general practices in parts of England, 
were invited to provide a home collected urine sample or vulval swab specimen, or 
both, for testing for Chlamydia trachomatis.  The research health adviser visited each 
practice at the start, was available during the trial by telephone or in person, and 
carried out telephone follow up. 
The ClaSS trial found that people diagnosed with chlamydia infection in primary care 
settings can be managed there by trained staff who are supported by sexual health 
advisers.  These trained practice nurses carried out partner notification that is at least 
as effective as referral to a specialist health adviser and the practice nurse led strategy 
costs no more than referral to a specialist health adviser.  Their qualitative research 
showed that patients also preferred this strategy to clinic referral (a third of those 
referred for specialist partner notification did not attend the genitourinary medicine 
clinic).   
Comparing the ClaSS outcomes to our Irish pilot, show differences, which correspond 
with the organisation of primary care services in England and Ireland: the practice 
nurses in the English ClaSS study (with support from the RHA) were successful and 
participated fully in partner notification [21].  In contrast, the RHA was the main 
provider of the partner notification in the Irish study, which probably partly reflects 
the lesser level of practice nurse support in Irish GP practices. 
Partner notification by telephone worked well during the pilot with patients satisfied 
with the service, as reported in the post-pilot qualitative interviews with participants.  
A confirmed partner treatment rate of 0.5 contacts per index case was recorded. This 
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compares well with the target set by the NCSP of 0.6 and reflects the success of the 
partner notification model used in the pilot study.    
The use of community contact cards was not successful: the ClaSS study also found 
that contact slips were not useful for ascertaining contact treatment [21]. 
4.3.5 Developments in the field of chlamydia screening 
Several important papers have been published since the Research into the Optimal 
Setting for Chlamydia Screening in Ireland Pilot Study was commissioned by the 
Health Protection Surveillance Centre in late 2006. Two reviews of chlamydia 
screening studies [22;23] have concluded that the evidence is not yet sufficient to 
justify opportunistic or systematic chlamydia screening approaches. Optimism about 
the potential of opportunistic chlamydia screening to prevent serious morbidity 
(chiefly pelvic inflammatory disease [PID] in women) has been tempered. Estimates 
suggest that only 30% of PID is attributed to chlamydia [22].   
The results of the recent randomised control trial (RCT) of screening among students 
in London showed that most episodes of PID (30 of 38) were in women who tested 
negative for chlamydia at the start of the 12 month trial [18]. This concluded that 
“Policy makers might consider focusing on more frequent testing of those at higher 
risk, such as women with a new sexual partner or a recent history of chlamydial 
infection”. 
Mathematical models have estimated that coverage of 26-43% (of the total target 
population of under 20 years olds or 16-24 year olds, not just of those attending 
general practices) would be needed to reduce chlamydia prevalence rates by 30% after 
one year [24;25].  Coverage rates of less than 10% of eligible attendees were 
estimated for practices in the Chlamydia screening in Ireland pilot study, i.e. those 
practices that had sufficient interest and enthusiasm to participate.   
Similarly low rates (4.9%) of uptake of screening in the target population of 16-24 
year olds were initially achieved across three phases of the English National 
Chlamydia Screening Programme [15] and “in contrast to predicted uptake of 50%, 
only 2.5% of 16 to 24 year olds were screened” over the course of one year [22].  
However as aforementioned uptake has increased significantly as reported in a more 
recent report (25), with recent NCSP coverage rates (2009/2010) of approximately 
47% and 25% of sexually active young women and men respectively
 
[15].
.
 
The appropriateness of chlamydia screening in Ireland will need to be reappraised as 
new evidence becomes available.  There are two current trials of both systematic and 
opportunistic chlamydia screening in the Netherlands [20] and Australia [26]; both 
involve multiple screening rounds and will provide essential information about the 
effectiveness of chlamydia screening. 
The Netherlands model is a systematic register based chamydia screening programme 
started in April 2008. Letters are sent annually to all 16 to 29-year-old residents of 
specific cities and selected municipalities. The letters invite sexually active persons to 
login to http://www.chlamydiatest.nl with a personal code and to request a test kit. In 
a lower prevalence area, test kits can only be requested if the internet-based risk 
assessment exceeds a predefined value.  The overall participation rate for the first 
screening round was 16%. 
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The Australian Chlamydia Control Effectiveness Pilot (ACCEPt) is a cluster 
randomised trial with the aim of determining whether annual recall for 16-29 year old 
women and men attending practices can increase chlamydia screening to levels that 
are high enough to reduce its prevalence in this population [27]. 
A useful starting point for Irish policy makers and programme planners when 
considering the results of the Chlamydia Screening in Ireland Pilot Study is the 
European Centre for Disease Control’s guidance document on Chlamydia control in 
Europe [28], which has outlined a chlamydia control framework with four levels:  
Level A primary prevention:  health promotion, school programmes and condom 
distribution 
Level B case management:  surveillance, diagnostic services, clinical services, and 
patient and partner management services 
Level C opportunistic testing:  offering chlamydia tests to people attending clinical 
settings for other reasons, so as to identify and treat asymptomatic cases 
Level D screening programme:  “This build on Level C with the addition of the 
organised provision of regular chlamydia testing to cover a substantial 
proportion of a defined population, with the aim of reducing chlamydia 
prevalence in the population”. 
The report states that decisions on moving from one level of control to the next should 
be based on “a rigorous appraisal of the evidence for effectiveness, cost-effectiveness 
and harms”. 
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5. Conclusions 
The Chlamydia Screening in Ireland Pilot Study has demonstrated that chlamydia 
screening and provider initiated testing is acceptable to young people when they 
attend a range of clinical services – general practices, family planning clinics and 
student health services.  The study has also demonstrated substantial challenges for 
primary care providers.  Feasibility for providers would depend on addressing a 
number of factors as described below.   
 Urine testing should be available to all clinical settings.  
 Provider training in sexual health is essential. 
 Partner notification would be optimally managed by designated health advisers, 
who could be given a geographical (e.g. a regional) responsibility. 
 Well designed incentives (training and supports for partner management are as 
important as money) are necessary, enabling practices to offer screening. 
 Offering a STI test to an asymptomatic (but at-risk) patient involves 
significant costs.  These have to be borne by one or more of the following: 
o the patient – those most at risk (16-24 year olds in the international 
literature) are least able to pay, especially in the economic climate of 
2010-11 
o the provider– the major costs for diagnosis (laboratory test) and 
treatment (antibiotics) cannot be covered by the provider 
o The state – detection and treatment of chlamydia is a public as well as 
a private good. Chlamydia notifications are growing rapidly.  However 
the economic analysis illustrates a high cost per QALY (€94,717) 
which is unlikely to be considered as cost-effective by government 
decision makers.  
 The decision to offer screening is influenced by both the context of the 
patient’s consultation and the provider’s perceptions of patient’s willingness to 
accept.   
Given the shift back to the importance of identifying and testing those at higher risk of 
chlamydia infection – but noting the contra-arguments (both epidemiological and 
sociological) to a risk factor pre-screening approach in Irish settings–there appears to 
be a strong case for approaches that combine demand-side (patient) with supply-side 
(provider) interventions.  These would focus on: 
o Demand-side: health promotion focusing on primary prevention (including 
regular use of condoms) and secondary prevention (getting tested after casual 
unprotected sex or when forming a new sexual partnership). 
o Supply side:  enabling men and women get tested in a range of primary care 
settings, where providers have been trained and enabled to maximise 
acceptability and avoid contributing to stigma effects on young people. 
 
Chlamydia screening is acceptable to young people in non-clinical settings, as part 
of sexual health awareness activities in Higher Education Institutes (HEIs).  It is also 
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more cost effective than screening in clinical settings (€34,486 per QALY gained). 
Given the experience of the Chlamydia Screening in Ireland Pilot Study, where large 
numbers of young people were quickly, easily and unobtrusively screened during such 
an event, the potential for extending this model of screening into other non-clinical 
and clinical settings is an area for exploration.  However, as noted in the Economic 
evaluation, ‘pee-in-a-pot’ screening has lower coverage in the target population than 
the base-case strategy (primary care settings) and is less effective in identifying 
infection and reducing overall prevalence levels.  
Of interest, the recent analysis of NCSP data by Johnson et al found that the greatest 
proportion of male tests were in university (27%) but this only identified 11% of total 
male positives [29].  More chlamydia-positive males were diagnosed through 
healthcare services despite fewer numbers of tests. Johnson et al. thus advised the 
future prioritisation in UK of increasing male testing in healthcare settings. 
5.1 Limitations 
The major and unavoidable limitation of this study was that only 18-29 year olds were 
included in the screening pilot.  The age restriction, which prevented us screening 16 
and 17 year olds, was dictated by legal advice, which precluded research on under 18 
year olds without parental permission.  
A further limitation is that the study was conducted in urban and rural settings in the 
Galway region which may not be representative of all parts of Ireland.  Positivity rates 
from various countries including Ireland [30;31]  have reported higher chlamydia 
notification rates in urban working class settings. Of note, these rates included 
symptomatic and asymptomatic cases and are not prevalence rates. These limitations 
highlight the need for further prevalence studies in a range of age groups, 
geographical and socio-economic settings.  
Interviews with health care providers and screened participants may have been subject 
to selection bias, whereby those with more negative views or experiences on testing or 
on the pilot may not have consented or volunteered to be interviewed. 
Vulvo-vaginal swabs were not used in this study because of validation concerns at the 
time of planning.  However this method has equivalent sensitivity to cervical swabs 
and thus should be considered for acceptability testing in any future screening work. 
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Appendices 
Appendix A.  Patient information leaflet on chlamydia screening 
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Appendix B. Patient Information leaflet on ‘Receiving your result’ 
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Appendix C. Chlamydia Request form  
 
Chlamydia Screen form  
Section 1. Staff & Patient to complete                                                                                                                
Clinicans Copy 
 
   
Site code/ Pt. ID           /        
 
Surname            Forename    
 
Specimen taker:  GP       Nurse    Patient  
 
Reason for test:  Screen          Contact   
 
Specimen type: Urine     cervical swab      vulva-vaginal swab  
 
Sex:           M     F   
 
Staff: Please estimate all the time taken to complete the screening test process.    
minutes. 
             
How would you like to receive your results?  Please tick your preference 
                                                                                                                                                     
Negative Result                                  Positive Result/ Appointment                               
 Phone call                                       Phone call /appointment                  
 Text message (if available)                 Letter/appointment                          
 Call back                           
 
Mobile phone no.                  Landline   
               
Address for correspondence with letter only   
                                                                         
 
                                                                 All data will be held confidentially 
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Appendix D.  Patient form for risk factors  
 
 Patient  Card                  Patient to complete                  
Instruction 
Please answer the questions below. 
All information is anonymous. 
 
Site Code/ Pt. ID           /        
 
Date of Birth    / /      
 
Country of birth    
 
Sexual History 
How many sexual partners have you had?   
 
Have you had sex with a new partner in the last 3 months? 
 
Yes            No            
 
Have you had sex with 2 or more different partners in the last 12 
months? 
 
Yes           No      
 
Please tick if  you have had any of the following 
symptoms in the last week?   
 
Pain on passing urine    
Unusual discharge         
Please place in envelope provided 
Thank you 
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Appendix E. Sample of Treatment protocol used  
 
Treatment
Check if patient is pregnant 
or lactating
 
Treatment Options
 Check if allergic reaction  macrolide antibiotocs
Taking ergot derivatives 
YES  
Erythromycin 500 mg qds x7 
days
Amoxycillin 500 mg tidx 7 days 
may not eradicate infection
 
Azithromycin 1g
(4 x 250mg) Give and observe 
ingestion during consultation 
Advise to avoid antacids
May interact with cyclosporin, 
digoxin, warafin and trefenadine
Doxycline (Vibramycin) 100 mg bd x 
7 days
Advise to avoid antacids
Check;
 On OCP
Avoid SI 7 days after treatment
Avoid SI until partner treated
Barrier contraception 
NO
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Appendix F. Community Contact card used for study  
 
Back 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Front of card  
Contact Card 
Community Contact Card  
CODE: 
____________________________
________________       Contact details: 
STI Clinic: 091 525200 
Research Health 
Adviser:087 7413813   
         087 7413813 
You may have been 
exposed to an infection 
called Chlamydia. This is 
easily treated with                             
antibiotics. Please seek 
treatment and bring this 
card with you. 
 
 
         Dear Staff/GP,                                        
         If you have received this card from a patient 
         please call 087 7413813.  
         This is part of a research study. 
         Thank you.   
 
          Galway STI Clinic   091 525200  
         Monday 2pm-5pm  (appoint. only) 
         Wednesday 9am-12pm / 2pm-4pm (Walk-In)  
         Friday 10am-12pm (appoint. only) 
         STI Clinic, Ballinasloe (090) 9648200  
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Appendix G.  Protocol for RHA phone calls 
Protocol for Retest Phone call 
 
   
                     Code: ___ /______                    Date: 
 
 
1. Establish any new risk factors?  
   (unprotected sex with a existing partner or change of partner)                                                                         
 
 
 
 
2. Did the patient attend for further STI screening. 
    If so, results? 
 
 
 
 
 
3. Reinforce health education: 
 Barrier protection 
 Risk of PID with repeat infections 
 
 
 
4. Enquire about contacts (testing and treatment) 
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5. Long term advice for retesting  
    (Yearly checks for male & female /change of partner) 
 
 
 
6. Ask about interest in doing an interview  
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Appendix H.  Partner notification Outcome form and guidelines  
 
                                       Partner Notification Form 
 
 
INDEX CASE Site / Pt. ID: _____ /_____      Contact cards given______ 
 
Phone no._______________          Date of positive result:___________ 
 
Partner in last 6 months 
 
Regular partner: Yes          How long______                    No  
 
Last sexual intercourse: When___________ 
 
Number of sexual partners in last 6 months_______ 
  
Communication & Date:   
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
___________________________________________________________________ 
 
 
Partner 1    
First name:                          Phone no. _________ 
 
When____________            Condoms:  Never          Occasionally        Always  
72 
 
Patient referral                     Health Adviser referral   or Provider referral  
Contacts cards given:                                                                   
 
Communication & Date: 
 
 
 
 
Outcome: 
 Tested & treated              Refused treatment        Did not attend                    
 Treated only                     Unable to contact         Other, please specify   
                                                                                                                                                                                                                                              
 
 
 
 
         
Partner 2    
First name:                           Phone no. _________ 
 
When____________            Condoms:  Never          Occasionally        Always  
 
Patient referral                         Health Adviser referral   or Provider referral  
Contacts cards given:                                                                   
 
Communication & Date: 
 
 
 
 
Outcome: 
 Tested & treated              Refused treatment        Did not attend                    
 Treated only                     Unable to contact         Other, please specify   
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              Standards for good practice in partner notification  
 
 Partner notification (PN) should take place face to face and with the 
time and privacy necessary to discuss the issue. 
 Staff should explain that questions on sexual history are standard 
questions for every patient to establish who else might be at risk of 
chlamydia. 
 Permission should be sought if being referred to the research health 
adviser. 
 Reasons for non-referral are documented. 
 Provider referral is offered to all patients who may have difficulties 
notifying partners.  
 When discussing PN and follow up by phone check that the patient is in 
a position to have a private conversation, if not find out when it is 
convenient.  
 
Standard Questions to assess partner risk 
 
The following questions will be used to identify the risk of chlamydia to other sexual 
partners:  
Recent intercourse: When was the last time you had sexual intercourse?  
Number of partners: How many partners have you had in the last 6 months 
Precaution: Were condoms used? (regularly, never, occasionally) 
 
The outcome of PN should be followed up until partner attendance has been verified, 
if possible. This may be easier to do by telephone.    
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Appendix I. Winning poster for ‘‘pee-in-a-pot’’ campaign competition 
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Appendix J.  Testing pack for pee in pot days  
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Appendix K.   Image of t-shirts for peer volunteers 
P
 
EE EASY, SLEEP EASY 
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Appendix L. Topic guide for interviews with screened persons 
 
Topic guide for positive patient interviews:  screening experience   
 
Offering of test 
 Can you tell me about your initial response on being offered Chlamydia 
testing? 
 Who asked you if you wanted to take the test?  
o What did you think of how they offered the test?  
 How was the test offered? (explore timing, setting, appropriateness/ 
gender/age)/check covered how test went? 
o Were you given any information about Chlamydia testing, if so, what 
did you think of this information? 
o Thinking back to when you took the test, what came to mind about 
Chlamydia? 
If at home probe; 
 For whether they kept the test private. 
 How convenient it was to drop the test back  
 How test was returned/feelings about this method [handing into 
receptionist]. 
Decision 
 Why did you decide to accept the test (explore feelings/concerns/other 
factors)? 
 Did you consider refusing and why? 
 
Waiting period 
 How did you feel waiting for your results? Or can you describe waiting for 
your result? 
o Did you have any expectation of the result? 
 While you were waiting for your results did you tell anyone that you had taken 
the test [If no: explore why. If yes: explore who was informed]? 
 
Notification 
 Could you describe to me the experience of getting the results?  
o (how did you receive your results and by whom?) 
o (how did you feel about that?) 
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 What was your reaction to receiving a positive result? / explore feelings) 
 What was your experience of the treatment/counselling given?  
 Do you feel you were prepared for you positive result? (if not, what could 
have been dine to prepare you more?) 
 (Thinking back can you remember what advice you received?) 
 
 
Partner notification  
 Did a HCW talk to you about informing your previous and current 
partners?(setting or Dee / telephone advice given) 
 What did your think of the information (if any) you were given and of the advice? 
 Was it helpful to you? 
 Were you given contact cards (explain/ did you use them? Do you know if your 
partners used them?  
 Who told your previous /current partner(s)?  
 How did you feel about contacting your partners and the reactions of partner(s) (if 
relevant) 
 Did you feel supported? Any suggestions on how else it could be done? 
 
Other STI testing 
 Did you get tested for other STI’s? 
 Where? What was your experience of getting tested? (logistics) What  did you 
like to dislike of he experience   
 Did you have any expectation of the STI clinic? 
 
Retesting 
 Have you done another test for Chlamydia and can you tell me about 
this?(logistics, feelings) 
 How did you feel about your retest result? 
 
 
Impact of positive result 
 What difference if any, has knowing you have had Chlamydia made? 
 Did you tell anyone about your result other than your partner [who/for what 
reasons?] 
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 What are your feelings now about deciding to be screened? (explore regret 
etc.) 
 Would you take the test again?  
 
Summary 
 On a future screening process, do you have any further advice for us? 
 Was there anything you would like to discuss? 
